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Molecular and Cell Biology  
ABSTRACT 
Introduction: Human saliva contains a variety of microorganisms and salivary proteins 
implicated in oral health and disease. The oral bacterium R. mucilaginosa harbors 
glutamine endoprotease activity degrading salivary proline-rich proteins (PRPs) rich in 
glutamine residues. PRPs share structural features with dietary gluten proteins, which 
trigger celiac disease (CD). Their structural similarities and shared destination of the 
gastrointestinal tract raise the potential for the involvement of PRPs in CD pathogenesis. 
The aims of this study were to: 1) Investigate to what extent R. mucilaginosa cell-
associated enzymes degrade gluten and abolish their immunogenicity; 2) Compare 
gluten-degrading enzyme activities and microbiomes in whole saliva (WS) from healthy 
and CD subjects; 3) Study the potential immunogenicity of salivary PRPs. 
Methods: Studies on gluten degradation by R. mucilaginosa comprised SDS-PAGE, RP-
HPLC, LC-ESI-MS/MS, and ELISA. Clinical studies were conducted with healthy and 
CD patient groups. Salivary hydrolytic activities were assessed towards Z-YPQ-pNA and 
gliadin-derived immunogenic 33-mer/26-mer peptides. Oral microbiomes were analyzed 
 vii 
 
by 16S rDNA sequencing. Induction of cytokines (TNF-α, IL-10, IFN-γ, and IL-21) by 
PRPs was studied in peripheral blood mononuclear cells (PBMCs) collected from CD 
patients. 
Results: R. mucilaginosa cell-associated enzymes degraded gliadins/33-mer/26-mer, 
decreased their recognition by TG2 and abolished epitopes recognized by R5 antibody. 
WS showed no differences between healthy and CD patients with regard to activities 
relevant in gluten degradation, and salivary microbiome compositions were similar. PRPs 
protein patterns revealed minor differences that were not group-specific. Despite 
structural similarities, PRPs did not stimulate cytokines production by PBMCs, nor did 
they compete with gliadin-induced cytokine secretion. 
Conclusion: From a therapeutic view point, R. mucilaginosa cells and/or their gluten-
degrading enzymes may offer novel perspectives for CD treatment. From an oral 
physiological perspective, endogenous WS gluten-degrading activities were low and 
comparable between healthy and CD groups, suggesting such activities may not be 
sufficient for gluten digestion in vivo, and further supporting the dietary supplementation 
concept. PRPs do not seem to harbor gliadin-like elements relevant in CD pathogenesis. 
Deciphering the structural basis for the lack of immunogenicity of salivary PRPs is of 
interest to inform development of gluten proteins lacking immunogenic epitopes, and 
their design is discussed.  
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1.1 Celiac Disease  
Celiac disease (CD) is defined as a chronic small intestinal immune-mediated 
enteropathy induced by dietary gluten in genetically predisposed individuals (Ludvigsson 
et al., 2013; Meresse et al., 2012). Gluten is a heterogeneous mixture of proteins from 
wheat, rye and barley. In most people the duodenum is most severely affected, although 
often the jejunum is also involved. Celiac disease has been described as “a permanent 
intolerance to ingested gluten that damages the small intestine, characteristically inducing 
crypt hyperplasia and villous atrophy, and typically resolves with removal of gluten from 
the diet” (Rostom et al., 2006). 
 
1.1.1 Epidemiology 
CD is the most common food-induced enteropathy in humans (Willemijn Vader, 2003). 
The prevalence for CD has increased over time, which may be accounted for by 
improved screening methods and diagnostic tests. The current reported global prevalence 
of CD in children ranges from 0.31% to 0.9%, and in adults is approximately 1-2% in 
Europe and 0.4-0.95% in the USA (Dube et al., 2005; Hoffenberg et al., 2003; Lohi et al., 
2007; Tack et al., 2010). The prevalence of CD varies by race / ethnicity, with the highest 
prevalence among non-Hispanic Caucasians (Rubio-Tapia et al., 2012). A multicenter 
study conducted in the USA revealed that the prevalence of risk-associated serotypes in 
fist-degree and second-degree relatives of patients was 1:22 and 1:39 respectively 
(Fasano et al., 2003).  
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1.1.2 Etiology 
The etiology for CD is complex, since genetic, dietary and environmental factors are 
involved. The most dominant genetic risk factor for CD is related to the genotypes 
encoding the HLA class II molecules HLA-DQ2 (encoded by HLA-DQA1*0501 and 
HLA-DQB1*02) and HLA-DQ8 (encoded by HLA-DQA1*0301 and HLA-DQB1*0302) 
(Tack et al., 2010). Researchers initially found that certain HLA gene alleles are of higher 
incidence in CD patients compared to healthy controls (Falchuk et al., 1972; Keuning et 
al., 1976; Stokes et al., 1972; Tosi et al., 1983). Later the association of CD with select 
HLA-DQ genes was confirmed when it was shown that CD4+ T cells from CD patients’ 
intestinal biopsies respond to gliadins presented by antigen presenting cells (APCs) 
expressing  HLA-DQ2 or HLA-DQ8 (Gjertsen et al., 1994; Lundin et al., 1993; Lundin et 
al., 1994). About 90% of individuals with CD carry the HLA-DQ2 heterodimer, and most 
of the remaining patients express HLA-DQ8 (Sollid et al., 1989; Sollid and Thorsby, 
1993; Tollefsen et al., 2006). However, over 25% of the population carries HLA-DQ2 or 
HLA-DQ8, but only ~1% of the population develop CD (Kakleas et al., 2010; Monsuur 
et al., 2008; Wessels et al., 2014) , indicating that their presence is necessary but not 
sufficient for the development of the disease (Green and Cellier, 2007). Other genetic 
factors have been identified by genome-wide association studies, and are mostly immune-
related (e.g. genes of chemokines, cytokine receptors, and proteins involved in regulating 
B-cell and T-cell activation), but these only account for a small risk increase in 
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developing the disease (Garner et al., 2009; Hunt et al., 2008; Romanos et al., 2009; Tack 
et al., 2010; Trynka et al., 2009). 
The main environmental risk factor for CD is dietary gluten. Gluten are prolamin 
storage proteins in barley, rye and wheat and are omnipresent in the Western diet. They 
are of high nutritional content and give elasticity to dough and largely determine the 
baking quality of bread products. Gluten include a group of proteins divided into soluble 
gliadins and insoluble glutenins. Both gliadins and glutenins contain domains that cause 
inflammation in CD, which was demonstrated by the observation that fragments from 
gliadin and glutenins induced immune responses from CD4+ T cells of CD patients (Liu 
et al., 2014; Tollefsen et al., 2006; Tye-Din et al., 2010b; Vader et al., 2002). It has been 
reported that environmental factors, such as early gluten feeding practices (Akobeng et 
al., 2006; Challacombe et al., 1997; Ivarsson et al., 2002; Persson et al., 2002), infections  
with adenovirus 12, gastrointestinal pathogens including rotavirus, Campylobacter jejuni, 
and Giardia lamblia (Carroccio et al., 2001; Hernandez et al., 2008; Plot and Amital, 
2009; Stene et al., 2006; Verdu et al., 2007), as well as socioeconomic conditions 
(Kondrashova et al., 2008) may also modulate the onset and severity of CD.  
 
1.1.3 Clinical presentations 
The nature of the symptoms depends partially on the age of the subject. Infants and 
young children typically present with symptoms such as diarrhea, abdominal distention, 
malnutrition, and failure to thrive (Green and Cellier, 2007). Other symptoms in children 
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include vomiting, irritability, anorexia, and constipation (D'Amico et al., 2005; Green and 
Cellier, 2007). In adults, the main gastrointestinal symptoms are diarrhea, bloating and 
abdominal pain, though in comparison to children, extra-intestinal manifestations of CD 
are more prevalent. Malabsorption due to villous atrophy may lead to iron-deficiency 
anemia, osteopenia or osteoporosis, short stature, and weight loss. Other signs and 
symptoms felt to be more related to peripheral autoantibody effects than directly to 
malabsorption are ataxia, infertility, polyneuropathy, persistent aphthous stomatitis, and 
dental enamel hypoplasia (Barker and Liu, 2008; Green, 2005; Green and Cellier, 2007; 
Mangione, 2011; Murray, 1999). In children with subtle symptoms and adults in general, 
the diagnosis of CD is often delayed.  
 
1.1.4 Diagnosis 
While diagnostic tests and criteria for celiac disease are accurate and readily available, 
diagnosis is often not considered since the symptoms are diverse and may be similar to 
other gastrointestinal and non-gastrointestinal diseases. Serologic tests including IgA or 
IgG for deamidated gliadin peptide (dGP), tissue transglutaminase (TG2), as well as 
endomysial antibody (emA), are all highly accurate and have the potential to serve as  
primary tests for screening of at risk population (reviewed by Leffler and Schuppan, 
2010). Serologic markers can also help to monitor patients’ adherence to gluten-free diet 
(GFD) (Abdulkarim and Murray, 2003) although they are not highly sensitive for low 
level and intermittent gluten exposure.  While serologic tests have high sensitivity and 
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specificity in general, small intestine biopsy with intraepithelial lymphocytosis, crypt 
hyperplasia, and villous atrophy remains, is still the gold standard for diagnosis of CD, 
and individuals with high risk of CD should be recommended upper endoscopy with 
biopsy analysis regardless of their serologic results (Green and Cellier, 2007). Since 
HLA-DQ2 is identified in 90% of CD patients, and HLA-DQ8 is identified in most of the 
remaining (Sollid et al., 1989; Sollid and Thorsby, 1993; Tollefsen et al., 2006), HLA 
typing can also support diagnosis. However, since HLA-DQ2 and DQ8 are common in 
the general population and most do not develop CD, the predictive value of HLA typing 
is very low.  But negative HLA testing rules out celiac disease and can be used as an 
adjunctive test, especially in individuals already on a gluten free diet, for whom serologic 
tests and biopsy can be expected to have normalized (Abdulkarim and Murray, 2003). 
 
1.1.5. Treatment of CD – the gluten-free diet 
The only current therapy for patients with CD is strict adherence to a gluten-free diet 
(GFD). Complete gluten exclusion from the diet is effective in that intestinal 
inflammation subsides in the majority of patients. While effective, a GFD has a number 
of limitations and impacts on patients’ lives, such as reduced nutritional contents, 
affecting social activities, the relatively high cost, and the limited availability of gluten-
free products (Gass et al., 2007; Schuppan et al., 2009). Gluten contamination is 
furthermore hard to avoid due to the ubiquitous distribution of gluten in food sources and 
 7 
 
ongoing symptoms and enteropathy due to inadvertent gluten exposure are common 
(Chand and Mihas, 2006). 
 
1.2 Gluten: the pathogenic mechanism  
In CD, gluten-derived peptides promote an inflammatory reaction in the small intestine, 
involving the innate and the adaptive immune systems (Figure 1) (Green and Cellier, 
2007; Koning et al., 2005; Schuppan et al., 2009). In the generally accepted 
pathophysiology of gluten peptide toxicity, gluten peptides reaching the lamina propria 
are first modified by transglutaminase 2 (TG2). As indicated above, the majority of CD 
patients express HLA-DQ2 (~90%), and the remainder of the patients are HLA-DQ8 
positive (Meresse et al., 2012). Both HLA-class II molecules have a preference for 
negatively charged residues (Koning, 2003). Enzymatic modification of gluten in vivo by 
TG2 converts glutamine (Q) to glutamic acid (E), a negatively charged residue, thus 
facilitating binding of these gluten-derived peptides to HLA-DQ2/HLA-DQ8 on antigen 
presenting cells (APCs) in the lamina propria (Molberg et al., 1998; van de Wal et al., 
1998a)). Subsequently CD4+ T cells recognize the antigen presented in this HLA context, 
and are activated. The activation leads to the secretion of Th1 cytokines like interferon-
gamma (IFN-γ) (Nilsen et al., 1998; Wapenaar et al., 2004). The Th1 cytokines further 
leads to cell mediated cytotoxicity and increased release and activation of matrix 
metalloproteinases in myofibroblasts ultimately leading to mucosal remodeling and villus 
atrophy (Meresse et al., 2012; Qiao et al., 2012; Schuppan et al., 2009). At the same time, 
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a Th2 response leads to production of antibodies to gliadin and deamidated gliadin and 
autoantibodies to TG2 which have diagnostic and pathogenic significance.  Besides 
adaptive immune responses, the intestinal epithelium along with dendritic cells and 
macrophages (Di Sabatino et al., 2006; Schuppan et al., 2009) secrete increased levels of 
IL-15, which leads to up-regulation of NK-G2D on intraepithelial lymphocytes (IELs) 
and MIC-A on enterocytes, resulting in an enhanced innate immune response in the 
intestinal epithelium (Abadie et al., 2011; Abadie et al., 2012). It has been proposed that 
gliadin component p31-43 would directly trigger innate immunity in CD since it rapidly 
induced expression of IL-15 in duodenal biopsies (Londei et al., 2005; Maiuri et al., 
2003). More recent evidence shows that non-gluten components in cereals, specifically α-
amylase/trypsin inhibitor (ATI), also induce innate immune response (Junker et al., 
2012). 
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Figure 1. Pathogenesis of CD. Gluten-derived peptides that are resistant to digestion 
reach the lamina propria where they are crosslinked to- or deamidated by TG2. The 
deamidated peptides bind with high affinity to HLA-DQ2 or HLA-DQ8 on APCs, and are 
presented to CD4+ T cells. Activated T cells secrete Th1 cytokines, inducing the release 
of MMPs by myofibroblasts leading to mucosal remodeling and villus atrophy. Th2 
cytokines from CD4+ T cells drive the production of anti-gluten and anti-TG2 antibodies 
by B cells. APCs produce IL-15, causing increased intestinal epithelial apoptosis and 
permeability. Other cytokines such as IL-18, IFN-α, or IL-21 may play a role in 
polarizing and maintaining the Th1 immune responses (Figure and illustration from 
Schuppan et al., 2009). 
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1.3 Gluten chemistry  
The unique primary structure of gluten characterized by a high content of proline (P) and 
glutamine (Q) is closely related to their pathogenesis in CD. Early studies indicated that 
heated or digested gluten peptides were still toxic, indicating that antigen epitopes were 
non-conformational and likely of short length (Wieser, 1995). It has now been 
demonstrated that T cells derived from duodenal biopsies from CD patients react to a 
variety of peptides derived from α/β-, γ- and ω-gliadins as well as from HMW- and 
LMW-glutenins, with peptides derived from gliadins being among the most 
immunogenic (Anderson et al., 2000; Mitea et al., 2010; Tye-Din et al., 2010b). 
 
1.3.1 Gluten: gliadins and glutenins 
Gluten comprise a rather large complex family of proteins contained in wheat (Triticum 
aestivum), rye (Secale cereale), and barley (Hordeum vulgare), which are closely related 
and all belong to the Hordeae Tribe of Gramineae (also called Poaceae or grass) family. 
The complexity of gluten is due not only to the existence of multiple genes encoding 
gluten protein variants, but also to the fact that many grain cereal species are the result of 
interbreeding between closely related cultivars. Bread wheat (Triticum aestivum), for 
instance, is hexaploid consisting of three diploid genomes: AA, BB and DD (van Herpen 
et al., 2006). This polyploidy resulted from interbreeding of three diploid species, which 
are most likely T. monococcum or T. urartu (A genome), T. tauschii (D genome) and T. 
speltoides (B genome). Their genomes consist of seven pairs of chromosomes, giving rise 
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to 21 pairs of chromosomes (Payne et al., 1984; Payne et al., 1987). As a result, gluten 
comprises hundreds of protein components, from a different genetic background.  
According to differential solubility in alcohol solution (e.g. 60% ethanol) wheat 
gluten proteins are divided into alcohol soluble gliadins and alcohol insoluble glutenins. 
Gliadins are monomeric in nature whereas glutenins are linked by interchain disulfide 
bonds into oligo- and polymers (Huebner et al., 1977). Gliadin proteins are further 
subdivided on basis of mobility at low pH in gel electrophoresis into α/β-, γ-, ω1,2, ω5 
gliadins (Wieser, 1996). In wheat, the α/β- and γ-gliadins represent the major 
components, constituting 28%-33% and 23%-31% respectively, whereas the ω-gliadins 
are present in a much lower percentage, amounting to 7%-13% (Wieser, 2001) (Figure 2). 
Similar to gliadin, glutenin proteins are also heterogeneous in nature. Based on 
differences in molecular mass, they can be grouped into high molecular weight (HMW-
GS), and low molecular weight (LMW-GS) glutenins (Ribeiro et al., 2013; Shewry et al., 
1995). The HMW-GS include x-type and y-type, whereas the LMW-GS are further 
subdivided into B, C, and D groups according to their isoelectric points (pI) and 
electrophoretic mobilities in SDS-PAGE (Liu et al., 2010; Ribeiro et al., 2013) (Figure 
3).  
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Figure 2. Schematic structures of gliadin proteins (Adapted from Wieser, 2007; 
Anderson et al., 2013; Ferranti et al., 2007). 
 
 
Figure 3. Primary structures of glutenin sequences and a model for the interchain 
disulfide structures of HMW glutenins (         ) and LMW glutenins (●) (adapted from 
Wieser, 2007; Ferranti et al., 2007; Chen et al., 2010).  
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Genes encoding for the HMW subunits of glutenin are located at Glu-1 loci on the 
long arms of chromosomes 1A, 1B, and 1D. Genes encoding for LMW-GS, and ω- , γ- 
gliadins are tightly linked on short arms of chromosomes 1A, 1B, and 1D. The LMW-GS 
encoding genes are at Glu-3 loci, ω- and γ- gliadins encoding genes are at Gli-1 loci. 
Besides, genes encoding for α/β -gliadins occur at Gli-2 loci on the short arms of 
chromosomes 6A, 6B, and 6D (Ducros et al., 1983; Lafiandra et al., 1984; Payne et al., 
1984; Payne et al., 1987). From the above it is evident that gluten comprises a rather 
complex family of proteins, both at the gene level as well as at the protein level. 
 
1.3.2 Amino acid sequences of gluten proteins  
Gliadins and glutenins have an unusual amino acid composition with a high content of 
glutamine (Q), proline (P), and hydrophobic amino acids. Hence they are named 
prolamins (Shewry and Halford, 2002; Wieser, 1995). In the predominant gluten proteins 
(α/β-gliadins, γ-gliadins and LMW-GS), Q comprises 35-38% of the total amino acids, 
while P ranges from 13-17%, totaling approximately 50%. In ω-gliadins Q residues 
represent 44-56% and P residues 20-26%, totaling over 70%. The hydrophobic amino 
acids phenylalanine and tyrosine, and the neutral glycine together comprise about 8%-
25% of the gliadin structure (Wieser, 1995; 2007). 
The amino acid sequences of wheat gliadins have been divided into different 
regions (Figure 2). The sequence of α/β-gliadin and γ-gliadin are similar. They both 
contain a short non-repetitive N-terminal domain, a central domain with P and Q-rich 
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sequences, typically PFPQ3-6 in α/β-gliadin and  PFPQ1-2(PQQ)1-2 in γ-gliadin, and a C-
terminal domain with most of the charged amino acid residues. The Cysteine (C) residues 
form intrachain crosslinks (Anderson et al., 2013; Chen et al., 2010; Ferranti et al., 2007; 
Groschf, 1999; Wieser, 2007)). The ω-gliadin protein (Figure. 1, bottom) is structurally 
different from the other subtypes. They consist of a large percent of repetitive sequences 
rich in P, Q, E, F as well as a C-terminal domain without C residues (Anderson et al., 
2009; Ferranti et al., 2007; Hsia and Anderson, 2001). 
The glutenins are aggregated proteins linked by interchain disulfide bonds (Figure 
3). They have varying size ranging from ~500,000 to more than 10 million (Groschf, 
1999). The LMW-GS is similar to α/β-gliadin and γ-gliadin in size and amino acid 
composition. The C residues form both inter- and intra-disulfide bonds (Groschf, 1999; 
Wieser, 2007). The HMW-GS consist of an N-terminal domain (80-105 residues), a 
repetitive central domain of backbone (QQPGQG) with peptide inserts (e.g. YYPTSP, 
QQP, QPG), and C-terminal domain of 42 residues (Shewry et al., 1992; Wieser, 2007). 
The C residues can form disulfide bonds between HMW-GS and LMW-GS. 
 
1.4 Gluten immunogenicity in CD  
 
1.4.1 Indigestible domains 
Proline (P) has a unique structure with the side-chain cyclized back to the backbone 
amide. The conformational restriction imposed by P residues in proteins often restricts 
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their hydrolysis at bonds adjacent to P residues by peptidases (Vanhoof et al., 1995). The 
abundance of P residues in gluten are a major cause for the survival of relatively long 
immunogenic gluten peptides in the gastrointestinal canal (Arentz-Hansen et al., 2002; 
Sollid, 2002). Furthermore, the peptide bond C-terminal to glutamine (Q) is not a 
preferred cleavage site by mammalian digestive enzymes. For instance, the main human 
mammalian digestive enzymes, trypsin, chymotrypsin, pepsin and elastase, preferably 
cleave after charged residues (R/K; trypsin), hydrophobic residues (Y/F; chymotrypsin, 
and F/Y/W/L; pepsin), or A/G/S/V (elastases). As a result, gliadins and glutenins are only 
partly digested in the upper GI tract and yield relatively large peptides instead of single 
amino acids, di-, or tripeptides. By treatment of recombinant gliadins with gastric and 
pancreatic enzymes a few protease-resistant peptides, which also show high 
immunogenicity for CD patients’ T cells have been identified and structurally 
characterized (Shan et al., 2002; Shan et al., 2005; Arentz-Hansen et al., 2000; Arentz-
Hansen et al., 2002). A principal peptide discovered was a 33-mer 
(LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF) spanning residues 57 to 89 in α2-
gliadin (Shan et al., 2002). It harbors six nine-residue T-cell epitopes: PFPQPQLPY 
(Glia-α1a, one copy), PQPQLPYPQ (Glia-α2, three copies), and PYPQPQLPY (Glia-
α1b, two copies). A second, highly immunogenic protease-resistant peptide has been 
described, which is 26-mer (FLQPQQPFPQQPQQPYPQQPQQPFPQ) comprising 
residues 26-51 in γ5 gliadin (Shan et al., 2005). Five known epitopes are clustered in this 
peptide: QQPFPQQPQ (Glia-γ5, 1 copy), QQPQQPYPQ (Glia-γ3, 1 copy), 
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QQPYPQQPQ (Glia-γ5-like, 1 copy), YPQQPQQPF (Glia-γ2-like, 1 copy), and 
QQPQQPFPQ (Glia-γ4c) (epitope nomenclature according to Sollid, et al. 2012) (Figure 
4). The survival of gluten domains in the proteolytic environment of the stomach and 
small intestine is one of the principal contributors to the toxic features of these proteins.  
Figure 4. A selection of highly immunogenic gluten/gliadin domains (from Koning, 
2003) and 33-mer/26-mer sequences derived from α-gliadin and γ-gliadin, respectively. 
The identified T-cell stimulatory immunogenic domains all contain a high amount of 
consecutive PQ (in red). 
 
The protease-resistant gluten-derived immunogenic peptides could traverse the 
epithelium to reach the lamina propria. The mechanism of transport of these relatively 
large peptides has not been fully elucidated. It might occur through paracellular transport 
via defective tight junctions, through epithelial transcytosis, or via sampling by dendritic 
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cells in the lamina propria (reviewed by Schuppan et al., 2009). Immunogenic peptides 
reaching the lamina propria induce adaptive immune response through binding to HLA 
on APCs and activating CD4+ T cells. Deamidation of these immunogenic peptides by 
the tissue transglutaminase 2 (TG2) is a critical step in increasing their binding affinity to 
HLA-DQ2 and HLA-DQ8 on APCs. 
 
1.4.2 Gluten structural requirements for TG2 recognition 
TG2 is a ubiquitously expressed multifunctional calcium dependent enzyme which 
belongs to a large family of transglutaminases (Iismaa et al., 2009; Lorand and Graham, 
2003). Its possible role in CD was initially proposed based on the discovery that TG2 
activity was increased in CD patients compared to control, and gliadin peptides are 
preferred substrates for TG2 (Bruce et al., 1985). Furthermore, almost all CD patients 
develop IgA autoantibodies to the TG2 (Schuppan et al., 2009; Dieterich et al., 1997; 
Vitoria et al., 1999). Lastly, gluten epitopes treated by TG2 showed higher 
immunogenicity for CD patients-derived gliadin T cells (Anderson et al., 2000; Arentz-
Hansen et al., 2000; Arentz-Hansen et al., 2002).  
At pH values below 7.3 (e.g. in the lumen of the small intestine, where it is 6.6) it 
mainly mediates deamidation of specific Q to E, thus introducing negative charges in 
gluten proteins (Evans et al., 1988; Fleckenstein et al., 2002; Iismaa et al., 2009). The 
spacing between Q and P, the two most abundant amino acids in gluten, dictate TG2 
recognition. In the sequences QP, QG, QXXP and QXXG (X represents any amino acid), 
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the Q is not a target for TG2, while in the sequences QXP, QXXF(Y, W, M. L, I or V), 
QXPF(Y, W, M. L, I or V), the Q is a very good target for deamidation (Vader et al., 
2002). Applying this principle, the glutamines in an α and a γ-gliadin protein are 
highlighted, according to their predicted likelihood of deamidation by TG2 (Figure 5). A 
green Q appears in the QXP, QXXF(Y, W, M. L, I or V) context and is likely 
deamidated. A red Q is present in the QP, QG, QXXP or QXXG are less likely to be 
deamidated. A blue Q appears in the QXPG context and may or may not be deamidated, 
since QXP would be recognized but a G in the fourth position is a non-preferred 
configuration (Vader et al., 2002). As shown in Figure 5, the alpha- and gamma-gliadins 
include a high percentage of glutamine (green) as potential deamidation sites by TG2.   
Figure 5. Theoretical TG2 recognition of gliadins. Both gliadins have a high content of Q 
preferred by TG2 (marked with green). The immunogenic domain 33-mer and 26-mer are 
underlined.  
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1.4.3 Structural requirements for DQ2/DQ8 binding 
After deamidation by TG2, the gluten-derived peptides have a higher binding affinity to 
HLA-DQ2 and HLA-DQ8 on the cell surface of APCs, and the peptide-DQ complex 
further activates CD4+ lymphocytes. In this process, P and Q are still important guiding 
residues.  
 By sequencing the natural peptides eluted from HLA-DQ2 and introducing single 
amino acid substitutions it was discovered that DQ2 has a preference for negatively 
charged residues at positions 4 (or aliphatic), 6 (or P), and 7 in its binding pocket, as well 
as bulky hydrophobic amino acids at positions 1 and 9 (van de Wal et al., 1996; Vartdal 
et al., 1996). In the identified 25 HLA-DQ2 restricted T cell epitopes from gluten, avenin, 
hordeins, and secalins (Sollid et al., 2012), the amino acid in position 1 is most frequently 
a P residue. Glutamic acid (E) residues derived from Q by TG2-mediated deamidation, 
are most abundant in position 4 and 6. P in position 6 and 8 would facilitate the 
deamidation of Q in position 4 and 6 (Stepniak et al., 2008). The P residue is not found at 
positions 2, 4, 7 and 9 suggesting that such peptides either don’t fit well into the pocket 
and/or are not immunogenic.  
Less is known on the HLA-DQ8 binding motifs. HLA-DQ8- restricted T cell 
epitopes have been found in -gliadins, γ-gliadins; and HMW–glutenins (Henderson et 
al., 2007; Sollid et al., 2012; Tollefsen et al., 2006). Although HLA-DQ2 and -DQ8 both 
have a preference for negatively charged residues, DQ2 mainly prefers such residues at 
anchor positions 4, and 6, and HLA-DQ8 at positions 1 and 9 (Godkin et al., 1997; 
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Henderson et al., 2007; Tollefsen et al., 2006).  In the DQ8 epitopes, simultaneous 
deamidation of Q residue at positions 1 and 9 shows greater stimulation of T cell activity 
than does a single deamidated Q at either position (Henderson et al., 2007; Tollefsen et 
al., 2006).  
 
1.4.4 Gluten T cell epitopes 
Both transglutaminase-mediated deamidation and HLA-DQ binding are important steps 
in CD pathogenesis although the exact mechanisms leading to T cell activation is not well 
clarified. A good correlation has been found between T-cell stimulation and deamidation 
of epitopes (Dorum et al., 2009; Dorum et al., 2010). The correlation of T cell stimulation 
and HLA-DQ binding affinity is less clear (Mitea et al., 2010).  
Decoding T cell epitopes is important for understanding the immune-pathogenic 
basis of CD and to facilitate the development of non-immunogenic HLA-DQ2/HLA-DQ8 
binding peptides. The identification of gluten T-cell epitopes is challenging due to the 
large diversity of this antigen. In vitro challenge of CD patients’ peripheral blood 
lymphocytes (Tye-Din et al., 2010b), small intestinal biopsies (Lindfors et al., 2012), and 
gluten-specific T cell lines generated from biopsies (Marti et al., 2005; Mitea et al., 2008) 
have been employed for the detection of responses to specific antigenic peptides. The 
antigens are usually treated with TG2 to mimic the in vivo deamidation process, and then 
incubated with a source of antigen presenting cells (APCs), such as an EBV-transformed 
B lymphoblastoid cell line (B-LCL) (Kooy-Winkelaar et al., 2011; Molberg et al., 2000), 
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and a T-cell line. T cell proliferation and/or Th1-associated cytokine production is 
evaluated to identify the T cell stimulatory capacity of these peptides (Molberg et al., 
2000).  
Using one of the above approaches, T cell stimulatory gluten-derived peptides 
have been discovered in α/β, γ-, and ω-gliadins as well as the LMW and HMW glutenin 
fractions. Some are listed in Figure 4, and an extended list of epitopes with references 
and new proposed nomenclatures have been published elsewhere (Sollid et al., 2012). 
Anderson and coworkers (2000) used synthetic peptides spanning α-gliadin for short term 
challenge of harvested peripheral blood lymphocytes, which elicits a transient population 
of anti-gliadin T cells allowing identification of antigenic T cell epitopes (Anderson et 
al., 2000). In a more recent study, the same group screened >16,000 potential toxic 
peptides from wheat, barley, and rye for their stimulation of polyclonal gluten-sensitive T 
cells from >200 CD patients, in an effort to elucidate the most immunogenic gliadin 
peptides. Interestingly, they found that an ω-gliadin/C-hordein derived peptide with the 
sequence QPFPQPEQPFPW was the most stimulatory gluten peptide after gluten 
challenge regardless of the source (wheat, barley, or rye). This discovery has significance 
for the development of peptide-based vaccine therapeutics (Tye-Din et al., 2010a). 
Besides wheat, a few immunogenic domains have been discovered in hordeins, secalins, 
and to a lesser extent in avenins, representing the storage proteins in barley, rye, and oats 
respectively (Koning, 2012).  
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The P- and Q-rich structural features of gluten distinguish these proteins from 
other protein sources that are also present abundantly in our daily foods such as proteins 
from soy, rice, meat and eggs. For instance, ovalbumin, which is the major protein of egg 
white, contains only 3.6% of proline and 3.8% of glutamine. While most dietary proteins 
show very limited structural similarities to gluten, their resemblance to a group of 
naturally occurring salivary proteins, called PRPs, is striking. In the following part, we 
will elaborate on the genetic and biochemical characteristics of the salivary PRPs and 
investigate whether immunogenic CD-associated signatures prevalent in gluten proteins 
can be observed in these proteins 
 
1.5 Salivary PRPs: gluten-like proteins 
 
1.5.1 PRPs in human saliva 
The PRPs are a major constituent of the human salivary proteome. The bulk fluid volume 
of saliva is produced by three pairs of secretory glands- the parotid, submandibular and 
sublingual glands. All main salivary proteins are produced by acinar cells in these glands, 
packaged in secretion granules and released under sympathetic and parasympathetic 
stimulation. Saliva is considered an important fluid for the maintenance of oral health, 
and its constituents have primarily been studied vis-à-vis such functions. Its production at 
one liter a day inevitably implies that saliva is not only surrounding the hard and soft 
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tissues in the oral cavity, but will also reach, after swallowing, the more downstream 
regions of the digestive canal.  
Human saliva contains on average 2-4 mg/ml of protein and of this, about 40% is 
composed of PRPs (Dawes, 2008; Helmerhorst and Oppenheim, 2007; Ruhl, 2012). 
Salivary PRPs can be divided into acidic PRPs (aPRPs) and basic PRPs (bPRPs), based 
on their charge and consequent differential affinity for cation- and anion exchange resins 
used for their isolation, respectively. Historically, the acidic PRPs were isolated first, as 
four groups referred to as PRP I, II, III and IV (Oppenheim et al., 1971), that included 
phosphorylated proteins (Isemura et al., 1980; Wong et al., 1979; Wong and Bennick, 
1980). Various peptides derived from basic PRPs, and a highly glycosylated isoform 
proline-rich glycoprotein (PRG) were isolated and sequenced shortly thereafter (Isemura 
et al., 1982; Kauffman et al., 1982; Kauffman et al., 1986; Kauffman and Keller, 1979; 
Kauffman et al., 1991; Maeda et al., 1985; Saitoh et al., 1983a; b; c). Due to their 
abundance, PRPs were among the first salivary proteins to be isolated and targeted for 
functional characterization. Still, as of yet, there is no solid functional assignment to the 
large variety of the peptides derived from basic and acidic PRPs present in human saliva. 
 
1.5.2 PRP genes  
As their name suggests, PRPs are rich in P residues constituting approximately 35% of 
their amino acid content, followed by glutamine (15%), and glycine (8%) (Azen, 1973; 
Oppenheim et al., 1971). The rather large PRP family is encoded for by 7 genes, PRH1, 
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PRH2, PRB1, PRB2, PRB3, PRB4 and SMR3B (Isemura and Saitoh, 1994; Isemura, 
2000; Maeda et al., 1985). The PRH genes encode for the acidic PRPs and the PRB and 
SMR3B (also called PBII) genes for the basic PRPs. The primary translation products of 
these genes vary in length from 150 amino acids (most acidic PRPs) to approximately 
400 amino acids (most basic PRPs), with the exception of the SMR3B product which is 
considerably shorter at 57 residues in length. The PRB genes are clustered near the acidic 
PRP genes on chromosome 12p13.2 in the order 5’-PRB2-PRB1-PRB4-PRH2-PRB3-
PRH1-3’ (Maeda et al., 1985). The SMR3B gene is located on chromosome 4q13.3, 
different from all other PRP genes (Isemura, 2000), perhaps pointing to a distinct 
evolutionary origin.  
 
1.5.3 Acidic PRPs – primary structures and post translational modification (PTM) 
The PRH1 and PRH2 genes both contain several common alleles. The PRH1 locus 
contains alleles Db, PIF, and Pa, giving rise to the proteins Db-s (s for “slow”, as 
compared to f for “fast”; see section on post-translational modification below), PIF-s, and 
Pa proteins respectively, while the PRH2 locus contains alleles PRP1 and PRP2, 
encoding for PRP1 and PRP2 proteins, respectively. As a result, the acidic PRP pattern is 
complex, yielding 18 potential PRP protein patterns (Hay et al., 1988; Hay et al., 1994). 
The primary gene products are 150 amino acids in length, with the exception of Db-s 
which is 171 residues long due to a 21-residue insert at position 82-102. The structural 
differences among the acidic PRPs are shown in Table 1. Position 4 carries an Asn in all 
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PRH1 encoded proteins and an Asp in all PRH2 encoded proteins. At position 25, a Leu 
is observed in Db-s and Pa, while an Ile is present in PIF-s, PRP1 and PRP2. Position 50 
is represented by an Asp in Db-s, PIF-s, Pa, PRP2, and by an Asn in PRP1. Lastly, Pa 
contains a Cys at position 103, causing it to dimerize in human saliva (Oppenheim et al., 
2007). At the PRH1 and PRH2 loci, the PIF and PRP1 alleles have the highest frequency 
of occurrence (0.67 and 0.76, respectively) (Hay et al., 1994), such that the double 
homozygous PIF/PIF/PRP1/PRP1 phenotype is the most common in the population. 
Additional polymorphic isoforms, arising from single nucleotide substitutions, have been 
identified (Iavarone et al., 2014).  
* PIF, Pa, PRP1 and PRP2 are 150 residues in length, differing only in a few residues. Pa 
contains a cysteine residue at position 103 and forms dimers. Db is longer with an extra 
20-residue repeat (rpt 61-68). 
 
Acidic PRPs are phosphorylated by a Fam20C Golgi casein kinase at positions 8 
and 22, with minor levels of phosphorylation at Ser 17 following phosphorylation of Ser 
22 (Brunati et al., 2000; Inzitari et al., 2005). PRP1, PRP2, Db-s, and PIF-s are post-
translationally cleaved after Arg-Pro-Pro-Arg↓ at residue 106 by proprotein convertases 
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in the Golgi apparatus (Chan and Bennick, 2001; Wong and Bennick, 1980). It leads to 
the 44 residue P-C peptide (identical in all isoforms) and the fast-migrating analogs of 
PRP3, PRP4, Db-f (f for “fast”) and PIF-f, respectively (Hay et al., 1988; Hay et al., 
1994). Intact as well as the truncated acidic PRPs can be detected in human salivary 
secretion. The Pa isoform is not prone to this cleavage due to the Arg-103→Cys 
substitution which eliminates the consensus sequence for convertase recognition at 
position 106. Overall, the acidic PRPs are an extended family of structurally highly 
homologous, P and Q-rich proteins, and share this feature with the basic proline-rich 
protein family in saliva. 
 
1.5.4 Basic PRPs – primary structures and PTM 
As for the acidic PRP loci, the basic PRB genes display different alleles. In contrast to the 
acidic PRPs, the basic PRP alleles have variable length. Based on size they are divided 
into small (S), medium (M) and large (L) alleles (Figure 6). The S, M and L isoforms 
result from different numbers of repeat domains in exon 3 of the basic PRP genes, which 
encodes the proline-rich portion (Kim et al., 1993). The repeat domains are P- and Q-rich 
and vary in length from 16 to 21 amino acids (48-63 bp) (Lyons et al., 1988). The PRB1 
and PRB4 genes are represented by S, M, and L alleles, the PRB3 gene by L and S 
alleles, and PRB2 by a single allele (L). The SMR3B gene product is small and does not 
contain repeat domains. 
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Figure 6. Schematic presentation of the primary structures of human salivary basic PRPs. 
White boxed areas: signal peptides; dark grey boxed areas: non-repeat domains; light 
grey boxed areas: repeat domains. The consensus amino acid sequences of the repeat 
domains are indicated. In PRB1L and PRB2L some of the repeat domains are interspaced 
with single proline (P) or serine (S) residues. Open circles: repeat regions missing in the 
truncated M-allelic isoforms; diamonds: repeat regions missing in the truncated S-allelic 
isoforms. Note in PRB4 that the missing segments in the M and S isoforms do not exactly 
match the repeat domains. (From Helmerhorst et al., 2010) 
 
Basic PRPs are also post-translationally cleaved in acinar cells into smaller 
fragments prior to being released into the duct lumen. In contrast to the acidic PRPs, the 
fragmentation of the basic PRPs is complete and no intact gene products can be detected 
in glandular salivary fluids. The PRB3 gene product is highly glycosylated and protected 
from enzymatic hydrolysis. Seminal work by various research groups have led to the full 
characterization of the intraglandular PRP fragmentation cascades of the acidic and basic 
PRPs and identified the targeted cleavage sites (Azen et al., 1996; Bennick, 1982; Inzitari 
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et al., 2005; Isemura et al., 1980; 1982; Isemura, 2000; Kauffman et al., 1982; Kauffman 
et al., 1986; Kauffman and Keller, 1979; Kauffman et al., 1991; Messana et al., 2004; 
Messana et al., 2008; Saitoh et al., 1983a; b; c; Stubbs et al., 1998; Wong et al., 1979; 
Wong and Bennick, 1980). All non-glycosylated regions of basic PRPs are cleaved at 
Arg-Ser-Xaa-Arg↓ (↓ indicates the site after which cleavage occurs) (Cai and Bennick, 
2004; Helmerhorst and Oppenheim, 2007; Stubbs et al., 1998), which is a typical 
cleavage site for protein convertases such as furin (Bresnahan et al., 1990) and studies 
with  a human submandibular cell line transfected with furin and PRB4S have suggested 
the involvement of furin in the processing of basic PRPs in vivo (Chan and Bennick, 
2001).  
 
1.5.5 Functions of salivary PRPs 
The post-translational modifications of the salivary PRPs don’t only contribute to protein 
polymorphisms, but are also important for their functions. Acidic PRPs, by virtue of 
being phosphorylated and carrying a net negative charge display affinity for the tooth 
enamel surface. They inhibit crystal growth on the enamel surface (Hay et al., 1987; 
Moreno et al., 1979), and participate in the formation of the acquired dental pellicle 
(Bennick et al., 1979; Bennick et al., 1983; Moreno et al., 1984). Their main functions are 
therefore attributed to the maintenance of tooth enamel integrity. An additional property 
of acidic PRPs is that they bind tannin (Bennick, 2002; Lu and Bennick, 1998), which is 
a plant polyphenolic compound that can bind and precipitate dietary proteins and other 
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proteins from solution. Specific and non-specific interactions between PRPs and tannins 
have been described (Cala et al., 2012). The tannin-PRP interaction leads to the formation 
of precipitates, reducing the harmful effects of tannins, and generating the tactile 
sensation of astringency.  
Like acidic PRPs, basic PRPs bind tannins and may play a role in their 
neutralization (Bennick, 2002). Otherwise the functions of basic PRPs are not well 
established, except for the heavily N-glycosylated family member PRP3 (or PRG). As 
mentioned before, by being glycosylated, it is protected from proteolytic fragmentation in 
the harsh environment of the oral cavity. Functionally, the glycosylated PRB3 protein, as 
well as other glycosylated proteins in saliva, act as a masticatory lubricant (Hatton et al., 
1985; Ruhl, 2012), protecting the tooth surfaces from abrasive forces during mastication, 
and preventing desiccation of mucosal surfaces.  Basic PRPs have furthermore been 
shown to exhibit some anti-viral activity (Gu et al., 1995; Robinovitch et al., 2001) and to 
bind to C. albicans (O'Sullivan et al., 1997), and various oral bacteria, in a strain 
dependent fashion, which may affect the colonization of oral surfaces by these 
microorganisms (Ruhl et al., 2004). Specifically it binds to oral streptococci and 
Fusobacterium nucleatum (Gillece-Castro et al., 1991; Murray et al., 1992) which could 
in turn either promote adherence to oral surfaces and/or facilitate their clearance from the 
oral cavity (Ruhl, 2012).  
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1.5.6 Species and tissue distribution of salivary PRPs 
Besides in humans, PRPs are found in the salivary secretions of monkeys (Belford et al., 
1984; Oppenheim et al., 1979; Oppenheim et al., 1982), rats (Fernandez-Sorensen and 
Carlson, 1974), mice (Mehansho et al., 1985), hamsters (Mehansho et al., 1987), rabbits 
(Rajan and Bennick, 1983), pigs (Fanali et al., 2008; Patamia et al., 2005), and deer 
(Austin et al., 1989). The tissue distributions of acidic and basic PRPs in human body 
fluids differ. Studies of PRP mRNAs revealed that acidic PRPs are expressed only in the 
salivary glands, whereas the basic of PRPs are also found in other secretions including 
nasal and bronchial mucus (Sabatini et al., 1989; Schenkels et al., 1995; Warner and 
Azen, 1984). Other tissues, including the stomach, duodenum, proximal ileum, distal 
ileum and colon, didn’t show evidence for salivary basic PRPs mRNA (Sabatini et al., 
1989). Acidic PRPs are found in saliva, but not in other body fluids including tear, nasal 
mucus, bronchial mucus, seminal plasma, cervical mucus, sweat and blood plasma 
(Schenkels et al., 1995), except that the lachrymal gland contains an mRNA encoding for 
a protein showing 45.5% similarity to human salivary acidic PRP1 (Dickinson and 
Thiesse, 1995; 1996). The different tissue distributions of the basic and acidic PRPs may 
be related to their different physiological functions. While acidic PRPs are involved in 
calcium binding and the formation of the acquired dental pellicle, the wider distribution 
of basic PRPs may imply a broader function for the latter proteins. The possible influence 
of salivary PRPs on gastrointestinal health cannot be excluded from their absence of 
expression in these tissues, given that human saliva is produced continuously and salivary 
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proteins and their fragments reach the more downstream regions of the gastro-intestinal 
tract when saliva is swallowed.   
 
1.6 Structural similarity of gliadins and PRPs 
PRPs show an amazing, as yet poorly recognized, similarity in primary structure to 
dietary gliadins. In Table 2, some of the similarities in the primary sequences of gliadins 
and basic PRP proteins are compared. It is rapidly evident that in both gliadins and 
salivary PRPs P and Q constitute the majority of amino acids in their compositions. It can 
also be observed that the P and Q residues appear frequently consecutively in the 
sequence in the XPQ context. In gliadins, which are composed of on average 307 amino 
acids, P makes up around 17% of the total amino acid content and Q around 30%. The 
basic PRP gene products (L isoform) are similar in size to gliadins, averaging 357 amino 
acids. In basic PRPs the average content of P and Q is reversed as compared to in 
gliadins: P comprises 36% as compared to 17% in gliadins whereas Q constitutes 15% as 
opposed to 30% in gliadins. P and Q together make up around 50% of total amino acids 
in both types of proteins. The similarity in composition is remarkable, given the 
completely different evolutionary origins of these proteins (Homo sapiens and Triticum 
aestivum).  
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Table 2. Characteristics of gliadins from Triticum aestivum 
and human salivary basic proline-rich proteins1 
Protein # a.aa %Q %P %(Q+P) #XPQ 
/-gliadins 288b 34 15 49 7-22 
-gliadins 276c 31 16 47 2-38 
ω-gliadins 356d 24 19 43 8-72 
PRB1 392 16 37 53 47 
PRB2 416 15 37 52 50 
PRB3 309 14 35 49 20 
PRB4 310 14 34 48 21 
a Including signal peptides 
b,c,d Average number of amino acids in /-gliadins (58 entries), 
-gliadins (110 entries), ω-gliadins (8 entries) 
From : Helmerhorst et al., 2010 
 
Both gliadins and PRPs contain repeat domains (reviewed by Chen, et al., 2010; Bennick, 
1987). The consensus sequences of the repeat domains are compared in Table 3. This 
comparison further highlights similarities, although differences are also readily apparent. 
The most prominent difference is that lysine (K) is frequently preceding the PQ sequence 
in basic PRPs, whereas the KPQ sequence is virtually absent in gliadin proteins. The 
repeat domains in PRPs are generally longer than those in gliadins (Table 3a, 3b). 
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1.7 Salivary PRPs and CD 
It is tempting to speculate that the structural similarities of these proteins endow them 
with certain similar properties. In this context, it is of importance to note that both 
salivary PRPs and dietary gliadins are susceptible to proteolysis by a group of newly 
discovered glutamine endoproteases. The protease activities are enriched in human dental 
plaque and are of microbial origin (Helmerhorst et al., 2008; Helmerhorst et al., 2010). 
Rothia bacteria were found to be among the most efficient in degrading gluten 
(Fernandez-Feo et al., 2013; Helmerhorst et al., 2010; Zamakhchari et al., 2011). Based 
on this observation, it was proposed that Rothia or its derived enzymes may potentially 
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be able to neutralize the deleterious effects of gliadins in vivo and could find therapeutic 
applications for the treatment of CD. Aside from the shared protease sensitivities, 
considering the remarkable structural similarity of salivary PRPs with gliadins, as well as 
the high amount of salivary PRPs produced and swallowed every day, it is of interest to 
investigate if PRPs would exhibit gluten-like properties which would be relevant in CD 
pathogenesis. In the following sections the PRP structures will be analyzed for their 
predicted recognition by TG2 and binding to HLA-DQ, which are critical steps in the 
inflammatory cascade leading to villous atrophy. 
 
1.7.1 Theoretical recognition of PRPs by human TG2 
To elicit CD, TG2 mediated deamidation is an important step, as it greatly increases the 
binding affinity of gluten-derived peptides to certain HLA molecules expressed on APCs. 
As discussed in the previous chapter, the recognition and deamidation of glutamine by 
TG2 is not a random process but dictated by the amino acid context of the target 
glutamine residues. In the sequences QP, QG, QXXP and QXXG (X represents any 
amino acid), the Q is not a target of TG2, while in the sequences QXP, QXXF (Y, W, M, 
L, I or V) the Q residue is a very good target for deamidation (Vader et al., 2002). 
Applying this principle, we investigated the theoretical TG2 recognition sites in acidic 
and basic PRPs. 
In basic PRP1 and acidic PRP1, some of the Q residues were identified as TG2 
preferred “Q” residues (marked in green) predicted according to the above rules. In 
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addition, we identified a rather large number of Q residues that appeared in the QGPP 
context, where it is unclear if the Q is or is not deamidated (since QXP is preferred, but 
QG and QXXP are not). Lastly, the residues in red are not preferred by TG2, since they 
are in QXXP, QP, QXG, or QG context. Overall this analysis shows that in contrast to 
gliadins, a large number of the glutamines in salivary proteins appear in the “QGPP”, or 
otherwise non-preferred sites for TG2 (Figure 7).  
 
Figure 7. Theoretical TG2 recognition of acid and basic PRP sequences. Compared to 
gluten proteins, few Q residues are preferred by TG2 (marked in green). Both proteins 
have a large amount of QGPP, which fits both TG2 preferred and non-preferred 
algorithms. 
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1.7.2 Theoretical HLA-DQ2/HLA-DQ8 binding sites in PRPs 
TG2 mediated deamidation of gliadins, which converts selected Q into E, is important for 
increasing the binding affinity to the HLA-DQ2 and HLA-DQ8 pocket. If the “QGPP” 
could be deamidated by TG2, both acidic and basic PRPs would gain negative charges, 
due to the high number of QGPP repeats in these proteins. It should be pointed out that 
the N-terminal domains in both acidic and basic PRPs naturally contain E residues, 
theoretically eliminating the necessity for protein deamidation by TG2 to generate a 
negatively charged peptide. A question of high interest is if the TG2 deamidated/naturally 
deamidated PRP peptides would fit into the DQ2 or DQ8 binding pocket. This will be 
further elaborated upon in the Discussion of Chapter 4. 
 
1.7.3 Alignment of salivary PRPs with immunotoxic gliadin epitopes 
In order to detect PRP domains that could possibly be implicated in CD, we aligned the 
full length salivary basic PRPs with a list of the most prevalent gliadin immunogenic 
domains. The alignment results are shown in Figure 8. The homology searches show that 
there is a percentage similarity of up to 50%, in a maximum stretch of overlapping 
regions of 17 amino acids. Acidic PRP alignments were also performed but showed lower 
percent homologies (not shown). The significance of this finding is that the PRPs 
domains that show the overlap are present in multiple copies in the repeated PRP 
domains.  
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Earlier, investigators showed structural similarities between a 12 amino acid 
peptide from α-gliadin and E1b protein from Adenovirus (Kagnoff et al., 1984).  Based 
on this it was postulated that infection with the virus could predispose to the development 
of CD through antigenic cross-reactivity. Noticeably, the similarity between E1b protein 
and gliadins occurred in a region located outside the major immunogenic epitope 
domains (Kagnoff, 1989). Our comparative investigations have elucidated salivary PRPs 
not only as gliadin-like proteins, but also as gliadin immunogenic domain-like proteins 
(Table 4). 
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Figure 8. Sequence similarities between salivary basic PRPs and selected gliadin 
epitopes. Basic PRPs (top sequences, bolded) are aligned with gliadin epitopes 
(underneath), and the amino acids that are homologous in both sequences are indicated 
with an asterisk. (From Helmerhorst et al., 2010) 
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1.8. Conclusion 
In summary, the glutamine-rich gliadins and PRPs share the susceptibility to proteolytic 
cleavage by oral glutamine endoproteases produced by bacteria colonizing the oral 
cavity.  One of the most efficient gluten-degrading species is Rothia mucilaginosa. 
Effective digestion of gluten by Rothia bacteria might abolish harmful gliadin proteins 
and facilitate the development of novel therapeutic adjuncts to a gluten-free diet.  
Endogenous gliadin-degrading enzyme activities in the oral cavity may differ between 
healthy and celiac patients. If so this could point to a physiological role of such enzymes 
in gluten digestion in vivo and be relevant in CD. Lastly, based on the gliadin-PRP 
structural mimicry PRPs may participate in the pathogenic mechanism of CD, for 
instance by eliciting inflammatory T-cell responses, or by ameliorating or dampening 
gluten-induced responses. An interesting additional function of PRPs, though beyond the 
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scope of this project, can be envisioned where PRPs may affect the induction of oral 
tolerance to gluten early on in life. This study represents a first investigation into the 
implication of salivary gluten-degrading enzymes and salivary gluten-like proteins in CD.  
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1.9. Study Aims 
 
Aim 1: To investigate to what extent R. mucilaginosa cell-associated enzymes degrade 
gliadins and abolish their immunogenicity. 
 
Aim 2: To compare oral microbiomes and endogenous gluten-degrading salivary enzyme 
activities in whole saliva (WS) from healthy subjects (HC), non-celiac GI subjects (GI), 
CD patients (CD), and refractory CD patients (RCD). 
 
Aim 3: To study the salivary PRPs protein patterns in HC, GI, CD and RCD patients’ 
saliva, and to explore the potential immunogenicity of parotid salivary proteins in CD. 
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CHAPTER II 
Effect of Rothia mucilaginosa Enzymes on Gliadin Structure, Deamidation and 
Immunogenic epitopes 
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2.1 Introduction 
CD is a T-cell mediated-inflammatory enteropathy caused by dietary gluten. Gluten, a 
heterogeneous mixture of glutamine- and proline-rich storage proteins from wheat, rye 
and barley, is the primary environmental cause of CD. CD has become the most frequent 
inflammatory intestinal disease with autoimmune features, affecting roughly 1% of most 
populations worldwide. At least 50 distinct gluten peptides can be deamidated by 
intestinal tissue transglutaminase which transforms them into peptides with an improved 
fit for the antigen binding groove of HLA-DQ2 or –DQ8 which is the necessary and 
predominant genetic predisposition of CD. The peptides presented in this context then 
trigger (deamidated) gluten specific T helper 1 (Th1) T cells that elicit and maintain the 
mucosal destruction with villous atrophy and crypt hyperplasia which is the histological 
hallmark of CD and which can prevent the effective absorption of nutrients (Abadie et al., 
2011; Green and Jabri, 2006; Green and Cellier, 2007; Schuppan et al., 2009). If left 
untreated, people with CD can develop further complications related to malabsorption 
such as osteopenia or  osteoporosis, anemia, steatorrhea and weight loss, and in some 
cases T cell lymphoma (Cellier and Cerf-Bensussan, 2006). Complete gluten exclusion 
from the diet is effective in that inflammation resides in the majority of patients. Yet, 
apart from the obvious sources, gluten is present in almost all refined foods, leading to 
severe dietary restrictions and in part social isolation of CD patients. Moreover, even on a 
strict gluten free diet, it is often impossible to avoid traces of gluten which can cause 
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symptoms of the disease (Tack et al., 2010). Therefore, therapies adjunctive to the gluten 
free diet are urgently needed. 
The unique feature of abundant proline and glutamine residues in their primary 
structures makes gluten peptides highly resistant to natural human digestive enzymes 
(Shan et al., 2002; Shan et al., 2005). This resistance results in intact immunogenic 
peptides surviving intestinal degradation. One therapeutic strategy for CD is oral enzyme 
therapy, which is aimed at hydrolyzing domains that resist digestion by pepsin, trypsin 
and chymotrypsin (Bethune and Khosla, 2012; Cerf-Bensussan et al., 2007). Protease-
resistant peptides of particular concern are a 33-mer from α-gliadin and a 26-mer from γ-
gliadin that each contain multiple copies of highly immunogenic epitopes (Shan et al., 
2002; Shan et al., 2005). Prolyl endopeptidases (PEP) cleaving gluten have been 
identified in various microorganisms, such as Flavobacterium meningosepticum, 
Myxococcus xanthus, Sphingomonas capsulata and Aspergillus niger (Gass and Khosla, 
2007; Stepniak et al., 2006). In addition, barley (Hordeum vulgare) produces an 
endoprotease, EP-B2, that cleaves preferentially after glutamine, especially with proline 
in P2 and P2’positions (Bethune et al., 2006). Both prolyl endopeptidases and EP-B2 are 
currently explored therapeutically, alone and in combination, to neutralize gluten toxicity 
(Siegel et al., 2006; Siegel et al., 2012). 
We have discovered other gluten-degrading enzymes that are associated with the 
human body and therefore may offer advantages over “foreign” enzymes. Thus the 
mixture of bacteria in human dental plaque can cleave gliadins, including immunogenic 
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gliadin derived 33-mer and 26-mer domains, into smaller fragments (Helmerhorst et al., 
2010; Zamakhchari et al., 2011). Twenty two gliadin-degrading strains were identified 
representing seven species: Rothia mucilaginosa, Rothia aeria, Actinomyces 
odontolyticus, Streptococcus mitis, Streptococcus sp., Neisseria mucosa and 
Capnocytophaga sputigena. Among these the Rothia species, which are considered 
harmless residents of the upper GI tract, were active in four complementary activity 
assays (Fernandez-Feo et al., 2013). Similar methods have later led to the identification 
of gluten-degrading species in human feces belonging to lactobacilli, steptococci, 
staphylococci, bifidobacteria and Clostridium species (Caminero et al., 2014). Gluten-
degrading natural microbial residents represent a promising new source of enzymes for 
luminal enzyme therapy since e.g. allergic or toxic reactions to these bacteria and their 
products are unknown. In addition, there is a distinct opportunity that such bacteria could 
be actively employed as probiotics.  
While the hydrolysis of the 33-mer and 26-mer peptides by Rothia bacteria was 
encouraging, it remained to be established to what extent cleavage would abolish the 
immunogenicity of the gliadin domains. The aim of this study is to determine the 
degradation cascade of gliadin/gliadin-derived immunogenic peptides by R. mucilaginosa 
and to investigate how it affects recognition by tissue transglutaminase (TG2), which by 
converting glutamine (Q) to negatively charged glutamic acid (E) residues in the primary 
immunogenic gliadin peptides, permitting their binding to HLA-DQ2/HLA-DQ8, thus 
serving as a valid surrogate for subsequent T cell activation.  
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2.2 Materials and Methods 
 
2.2.1 Cultivation of Rothia mucilaginosa 
Rothia mucilaginosa ATCC25296 was grown on Brucella blood agar plates (Hardy 
Diagnostics, Santa Monica, CA) for 48 h at 37°C under aerobic conditions. Cells grow in 
light greyish smooth colonies which are sticky in nature. 
 
2.2.2 Gliadins and derived peptides  
Mixed gliadins were obtained from Sigma (St Louis, MO, USA), and freshly dissolved to 
5 mg/ml in 60% ethanol. Gliadin-derived 33-mer 
(LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF), three fragments thereof designated 
pep1 (LPYPQPQLPY), pep2 (LQLQPFPQPQLPYPQPQ) and pep3 
(LPYPQPQLPYPQPQPF), and the gliadin-derived 26-mer 
(FLQPQQPFPQQPQQPYPQQPQQPFPQ) and three peptides thereof designated pep4 
(PQQPQQPYPQ), pep5 (QPQQPFPQQP) and pep6 (QPQQPFPQ) were synthesized at a 
purity of 95% (21st Century Biochemicals, Marlboro, MA). All peptides were dissolved 
in deionized water to 10 mg/ml, aliquoted, and stored at -80°C.  
 
2.2.3 Degradation of gliadins, 33-mer and 26-mer in solution 
R. mucilaginosa ATCC 25296 was harvested with a sterile cotton swab from 48 h 
cultures on blood agar plates and suspended in saliva ion buffer (SIB) containing 50 mM 
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KCl, 1.5 mM potassium phosphate, 1 mM CaCl2 and 0.1 mM MgCl2, pH 7.0 to an OD620 
of 1.2. Gliadins, the 33-mer or 26-mer peptide were added to a final concentration of 250 
µg/ml. The suspensions were incubated in a 37°C water bath at various time intervals 100 
µl aliquots were removed, boiled for 5 min, and lyophilized using a SpeedVac (Savant 
Farmingdale, NY). The gliadin mixtures were loaded onto pre-cast 12% Bis-Tris gels 
(Novex, InVitrogen, Carlsbad, CA) and the 33-mer/26-mer degradation aliquots were 
subjected to RP-HPLC. 
 
2.2.4 RP-HPLC 
RP-HPLC was carried out as reported previously (Zamakhchari et al., 2011). Briefly, the 
100 µl sample aliquots were mixed with 900 µl buffer A containing 0.1% (v/v) 
trifluoroacetic acid (TFA), filtered and analyzed by RP-HPLC using a HPLC Model 715 
(Gilson, Middleton, WI) and a C-18 column (TSK-GEL 5 µm, ODS-120T, 4.6×250 mm, 
TOSOHaas, Montgomeryville, PA). The column was equilibrated with buffer A. Peptides 
were eluted using a linear gradient from 0% to 55% buffer B containing 80% (v/v) 
acetonitrile and 0.1% (v/v) TFA over a 75 min time interval at a flow rate of 1.0 ml/min. 
The eluate was monitored at 219 and 230 nm (Unipoint version 3.3, Gilson). Fractions 
containing the degradation fragments were collected and lyophilized using a Speedvac 
(Savant). 
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2.2.5 LC-ESI-MS/MS 
The lyophilized fragments were dissolved in 25 µl of 5% acetonitrile and 0.1% formic 
acid. Mass spectrometry was performed using a capillary nano-flow liquid 
chromatography and electrospray ionization tandem mass spectrometer (LC-ESI-
MS/MS) as previously described (Helmerhorst et al., 2010). The raw MS/MS data of the 
peptide ions in each of the analyzed samples were searched against a limited database 
containing the 33-mer and the 26-mer sequences, using SEQUEST software (Bioworks 
Browser 3.3.1, Thermo-Finnigan). The X-corr values applied in the searches were 1.5, 
2.2 and 3.5 for Z = 1, 2, and 3, respectively. The deltaCn and peptide probability values 
were set at >0.1 and <0.01, resp.  
 
2.2.6 Crosslinking of gliadins, 33-mer, 26-mer, and derived peptides to MDC by 
TG2 
The TG2 used for these experiments was human recombinant TG2 (rhTG2, Zedira, 
Darmstadt, Germany). The preparation had a specific activity of 0.59 U/mg, where 1 U 
equals the formation of 1 µmole hydroxamate per min from Z-Gln-Gly-OH and 
hydroxylamine (Lorand and Campbell, 1971). Crosslinking to monodansylcadaverine 
(MDC (Sigma, St. Louis, MO) was determined as described (Dieterich et al., 2003), 
based on enhanced fluorescence of the dansyl group (Lorand et al., 1971). Briefly, 10 μM 
protein/peptide substrates, 30 μM monodansylcadaverine (MDC) and 20 μg/ml rhTG2 
(final concentrations) were dissolved in 100 μl buffer containing 0.1 M Tris HCl, 0.15 M 
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NaCl, 5 mM CaCl2, pH 8.8. Samples were incubated at 37°C and fluorescence was 
measured for 1 h at λex 360 nm and λem 535 nm using a Genios microtiter plate reader in 
the kinetic mode.  
 
2.2.7 Detection of peptide deamidation by mass spectrometry 
To examine deamidation directly, the peptides were incubated with rhTG2 as described 
above, except in the absence of MDC and in PBS containing 1 mM CaCl2 (pH7.2). After 
4 h incubation at 37°C, aliquots were dried and deamidation was assessed by LC-ESI-
MS. 
 
2.2.8 LC-ESI-MS 
Deamidation of samples was determined on a Q Exactive™ Hybrid Quadrupole-Orbitrap 
Mass Spectrometer (ThermoScientific, Tewksbury, MA). The sample aliquots were 
diluted 20 fold in  Buffer A (97.5% water, 2.5% acetonitrile and 0.1% formic acid) and 1 
µl was applied to an in house packed Accucore column containing C18 2.6 µm resin beads 
(ThermoScientific). The column has an internal diameter of 100 µm and is 20-25 cm in 
length.  Samples were applied using a Famos auto sampler (Dionex/LC Packings, Vernon 
Hills, IL). The HPLC pump used was an Accela 600 (Thermo Scientific). Peptides were 
eluted applying a gradient from 10- 65% buffer B (97.5% acetonitrile, 2.5% water and 
0.1% formic acid) over a 45 min time interval.   
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2.2.9 Enzyme-linked immunosorbent assay (ELISA)  
Sandwich and competitive ELISA assays were carried out employing the R5 monoclonal 
antibody (RIDASCREEN Gliadin and RIDASCREEN Gliadin competitive kits, R-
Biopharm AG, Darmstadt, Germany) (Valdes et al., 2003). The R5 antibody has a high 
binding activity towards the potentially celiac toxic epitope QQPFP. Experiments were 
performed according to the manufacturer’s instructions. For the sandwich ELISA 100 µl 
sample aliquots from the gliadin degradation experiment were centrifuged to collect the 
supernatant, diluted 1X with water, and then 500X with dilution buffer. Aliquots of 100 
µl were added to the anti-gliadin antibody-coated microtiter plate. The plates were 
incubated for 30 min at room temperature, washed with washing buffer, and incubated 
with 100 µl of peroxidase-conjugated secondary antibody for 30 min at room 
temperature. After washing, substrate solution containing tetramethylbenzidine was 
added, and after 30 min, 100 µl stop reagent was added and the absorbance read at 450 
nm. 
Epitope elimination in the 33-mer and 26-mer degradation mixtures was assessed 
with a competitive R5 ELISA. In this assay, the incubation mixtures were diluted 10X 
with water, then 500X with dilution buffer and 50 µl was added to a gliadin-coated 
microtiter plate, followed by the addition of 50 µl antibody-enzyme conjugate solution. 
Thus in this assay the experimental samples containing the 33-mer/26-mer fragments are 
competing with the gliadin substrate coated onto the microtiter plate for binding to the R5 
antibody. After incubation for 30 min at room temperature, wells were washed, followed 
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by the addition of substrate solution containing tetramethylbenzidine. Stop reagent was 
added after 10 min and the absorbance was read at 450 nm. 
 
2.2.10 Statistical analysis  
SPSS 15.0 software was used for statistical analysis. A correlation between the peak 
height and TG2-medicated crosslinking was tested using the Pearson’s correlation test. 
Differences in the ELISA assays between groups were determined by independent 
samples student’s t-test (two-tailed). Significance was set at p<0.05.   
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2.3 Results 
 
2.3.1 Degradation of gliadins, 33-mer and 26-mer peptides by R. mucilaginosa. 
To test and confirm the degradation of gliadin/gliadin-derived immunogenic peptides by 
R. mucilaginosa, we incubated the cells with gliadins, and 33-mer or 26-mer peptides. 
SDS-PAGE showed that the major ~37 kD band in the gliadin preparation, representing 
the α/β and γ-gliadins (Wieser, 1995), was gradually degraded into smaller fragments in a 
time dependent manner, with smaller molecular weight fragments appearing over time 
(Figure 9A). The 33-mer and 26-mer peptides were also degraded in a time-dependent 
fashion, as assessed by RP-HPLC (Figures 9B and 9C, respectively). The 26-mer and 33-
mer were almost completely degraded in 30 minutes and 8 hours, respectively, showing 
that the 33-mer was more resilient to proteolysis than the 26-mer peptide. Gliadins or 
26/33-mer peptides incubated with boiled R. mucilaginosa cells remained intact at the 
longest time point sampled (Zamakhchari et al., 2011) (data not shown). Overall, R. 
mucilaginosa has the enzymatic capacity to degrade mixed gliadins as well as 33-mer and 
26-mer domains into smaller fragments. 
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Figure 9. Degradation of gliadins, and 33-mer/26-mer peptides by R. mucilaginosa 
(ATCC 25296). Proteins/peptides (250 µg/ml) were incubated with R. mucilaginosa cells 
in suspension (OD620 1.2) at 37°C. At the indicated time points, aliquots were analyzed 
for protein/peptide survival. A, Gliadin degradation was monitored by 12% SDS-PAGE; 
B and C, 33-mer and 26-mer degradation, resp., were assessed by RP-HPLC. A * 
indicates the position of the intact 33-mer and 26-mer peptides. For better visibility, the 
individual traces were shifted. 
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2.3.2 R. mucilaginosa-treated gliadin/33-mer/26-mer show poor crosslinking to 
MDC  
To study if R. mucilaginosa-mediated degradation would affect gliadin/33-mer/26-mer 
recognition and modification by TG2, crosslinking to monodansylcadaverine (MDC) was 
performed. Cross-linking is a measure to predict TG2 deamidation in vivo, which is 
known to occur primarily in the mucosa and to significantly impact peptide 
immunogenicity (Molberg et al., 1998; van de Wal et al., 1998a). The experiment was 
conducted at pH 8.8, favoring cross-linking over deamidation activity of TG2 
(Fleckenstein et al., 2002). Cross-linking in the gliadin/33-mer/26-mer incubation 
mixtures was greatly reduced as the incubation time with Rothia progressed (Figure 10). 
The percent residual 33-mer/26-mer after the various incubation times (derived from 
Figures 9B and 9C) were plotted against the percent of the maximum MDC crosslinking 
rate (derived from Figures 10D and 10F). A perfect correlation was observed between 
both parameters, showing 50% reductions after 4.9 and 4.3 hours, respectively, for the 
33-mer, and 10.5 and 10.2 minutes, respectively, for the 26-mer (Figure 11).  
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Figure 10. Cross-linking of R. mucilaginosa-treated gliadin and 33-mer/26-mer 
degradation mixtures to MDC by TG2. Proteins/peptides were incubated in a suspension 
of R. mucilaginosa (OD620 1.2) at 37°C.  MDC crosslinking was determined in samples 
removed at the indicated incubation time intervals. A, C, E, kinetics of MDC crosslinking 
in the incubation mixtures; B, D, F, plots of the maximum rates of MDC incorporation 
over time, as determined from the kinetic plots in A, C and E.  
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Figure 11. Correlation of 33-mer and 26-mer degradation and crosslinking to MDC.  The 
percent survival of the 33-mer and 26-mer peptides (from Figure 9) were plotted against 
the maximum MDC incorporation rates (from Figure 10). For both the 33-mer and 26-
mer Pearson correlation analysis revealed r=0.992, and p<0.001 (n=8 per group). 
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2.3.3 Identification of fragments by LC-ESI-MS/MS 
The experiments above suggested that TG2 could not crosslink fragments of the 33-mers 
and 26-mers obtained after digestion with Rothia enzymes. For further confirmation, 
fragments in the 33-mer and 26-mer incubation needed to be identified and tested 
separately in the same assay. Degradation fragments in the t=0, 2 h and 5 h Rothia-
incubated samples were separated by RP-HPLC (Figures 12A and 12C). Peaks indicated 
by arrows were collected, dried, and the peptides characterized by LC-ESI-MS/MS 
(Figures 12B and 12D). Frequent cleavages occurred after glutamine residues, which is 
consistent with enzyme activities of the related species R. aeria, and with the fact that R. 
mucilaginosa rapidly cleaves the Z-YPQ-pNA substrate (Zamakhchari et al., 2011). It 
also confirms complete cleavage/inactivation of the immunogenic sequences. Prominent 
de novo generated peptides derived from the 33-mer and 26-mer were chemically 
synthesized for further analyses. The fragments chosen to be synthesized were relatively 
long, covering the middle, N-terminal, and C-terminal domains of the original 33-mer 
and 26-mer peptides, and more prominent in amount as derived from the peak heights in 
the RP-HPLC chromatograms. Synthesized fragments were designated pep1-pep3 (33-
mer derived) and pep4-pep6 (26-mer derived), indicated in boxes in Figures 12B and 
12D. 
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Figure 12. Separation and structural characterization of 33-mer and 26-mer degradation 
fragments. The 33-mer and 26-mer were incubated with R. mucilaginosa cells (OD620 1.2, 
37°C) for 0, 2 h and 5h. A and C, 33-mer and 26-mer degradation mixtures, resp., 
subjected to RP-HPLC. Peaks (p) indicated with arrows were collected. B and D, the 
amino acid sequence(s) of fragments in the collected peaks, derived from the 33-mer and 
the 26-mer, resp. determined by LC-ESI-MS/MS. Major proteolytic fragments, 
designated pep1-pep6 (boxed), were chemically synthesized. 
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2.3.4 Pure synthetic fragments show poor cross-linking to MDC 
Pure, chemically synthesized fragments pep1-pep6 derived from the 33-mer and 26-mer 
were tested individually in the MDC crosslinking assay. The pep1-pep6 fragments were 
all poor substrates for TG2, displaying an average rate of incorporation of MDC of 
6.18±2.20 AU/min (virtually no MDC crosslinking observed) as compared to 
97.75±10.72 and 84.17±3.25 AU/min for the 33-mer and 26-mer, respectively (Figure 
13). 
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Figure 13. Crosslinking of the 33-mer/26-mer and chemically synthesized fragments to 
MDC. The 33-mer and 26-mer and fragments thereof were incubated with TG2 in the 
presence of MDC, and crosslinking was measured by a fluorescence increase over time. 
A, 33-mer and pep1-3; B, 26-mer and pep4-6. 
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2.3.5 Detection of fragment deamidation by mass spectrometry  
Since the crosslinking to MDC is an indirect method to predict the recognition and 
modification of peptides by TG2, we also conducted mass spectrometry to directly 
observe the mass increase of +1 Da due to the conversion of a Q to an E residue. TG2 
effectively deamidated the 33-mer and 26-mer, each carrying 3 and 5 QXP sites, 
respectively (Figure 14A, 33-mer results shown). When the 33-mer was incubated with 
TG2, moieties with +1, +2 and +3 mass additions appeared and the non-deamidated form 
was no longer detected (Figure 14B). Pep1-pep3, were also deamidated by TG2, but in 
contrast to the 33-mer, the non-deamidated forms remained clearly detectable (Figure 
14D, 14F, 14H). In the case of peptide 1, most of the peptide remained in the non-
deamidated form. A few additional observations of interest were made. First, even 
without incubation with TG2, pep2 and pep3 showed minor levels of deamidation, as 
evidenced from the presence of peptides with  +1 Da mass additions (+0.5 m/z in the 
doubly charged ions) eluting just after the non-deamidated forms (Figures 14E, 14G). 
Second, TG2-incubated pep2 and pep3 displayed a minor degree of deamidation at a 
second glutamine as evidenced by small peaks with +2 Da mass additions (+1.0 m/z in 
the doubly charged ions; Figure 14F, 14H). Regardless of these minor species, a 
significant portion of TG2-incubated pep1-pep3 (and pep4-pep6; not shown) remained 
non-deamidated. Thus the MDC and MS approaches both indicated that deamidation of 
the major fragments was highly reduced, albeit not completely abolished, and suggested 
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that a strong reduction in immunogenicity is achieved after incubation with R. 
mucilaginosa. 
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Detection of peptide deamidation by LC-ESI-MS 
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Detection of peptide deamidation by LC-ESI-MS (continued) 
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Detection of peptide deamidation by LC-ESI-MS (continued) 
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Detection of peptide deamidation by LC-ESI-MS (continued) 
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Figure 14. Deamidation of the 33-mer and derived pep1-pep3 peptides, determined by 
LC-ESI-MS. A, C, E, G: 33-mer, pep1, pep2, pep3, respectively incubated without TG2. 
B, D, F, H: 33-mer, pep1, pep2, pep3, respectively incubated withTG2. Top panels: total 
ion chromatograms. Peak areas semi-quantitate the levels of the various species present. 
Lower panels: Zoom of the individual peptide ions, showing the isotopic variants. 
Deamidation of a glutamine residue adds a 1 Da mass to the peptide. For the 33-mer, 
zooms of the quadruply charged ions are shown, in which a 1 Da increase results in a 
+0.25 m/z shift. For pep1-3 the doubly charged ions are shown, in which a 1 Da increase 
is observed as a 0.50 m/z increase. The numbers of glutamic acids (E) in the various 
moieties are indicated.   
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2.3.6 Enzyme-linked immunosorbent assay (ELISA)  
Finally, to test the survival of potentially immunogenic epitopes, we used two ELISA 
based assays, a sandwich and a competition assay. The assays employed the R5 antibody 
which recognizes QQPFP, a potential celiac toxic epitope. A sandwich ELISA requires 
two epitopes, and is suitable for analysis of larger proteins (here for gliadin analysis). For 
the 33-mer and 26-mer, the competitive ELISA was employed, requiring only one 
epitope. The binding activity of mixed gliadin to R5 decreased as the incubation time 
with R. mucilaginosa increased, with a 20%, 82%, 97% reduction in the 30 min, 2 h and 
5 h incubated samples, respectively (Figure 15A).  
In the competitive assay binding to R5 antibody is inversely proportional to the 
absorbance measured at 450 nm. The 33-mer effectively competed with gliadins coated 
onto the microtiter plate for binding to the R5 antibody in the t=0 sample, and this ability 
disappeared gradually in the 8 h and 24 h samples, indicating abolishment of binding 
sites through degradation (Figure 15B). A maximum reduction in competing ability 
(increase in OD450) of 65% was observed. For the 26-mer, the binding epitopes were 
abolished more rapidly, as evidenced by a near complete reduction in competition in the 
5 h degradation mixture (Figure 15C). 
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Figure 15. Assessment of the survival of epitopes by R5 antibody ELISA. A, Gliadin 
degradation mixtures were analyzed for R5 antibody binding activity, which is 
proportional to the absorbance at 450nm. B and C, the 33-mer/26-mer degradation 
mixtures, resp., were analyzed for R5 antibody binding in a competitive ELISA, where 
binding is inversely proportional to the absorbance at 450 nm.  
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2.4 Discussion 
CD is induced by gluten-derived immunogenic peptides reaching the small intestine. 
Although some gluten peptides are highly resistant to mammalian digestive enzymes, our 
study indicated that oral microbes express such activity and are capable to further digest 
these immunogenic domains. In the present study, besides elucidating the proteolytic 
cascade of gliadin, 33-mer and 26-mer degradation by R. mucilaginosa, we also studied 
the possible influence of this hydrolysis on downstream processes relevant in CD, 
measured by TG2 modification and R5 antibody binding activity. After degradation of 
gliadin, 33-mer and 26-mer peptides by R. mucilaginosa, their modification by TG2 was 
reduced, and recognition by the R5 antibody was greatly diminished.   
The TG2-mediated enzymatic modification is a critical step in increasing the 
binding affinity of gluten peptides for HLA-DQ2 (-DQ8) on antigen presenting cells 
(APC) and subsequent activation of T-cells (Schuppan et al., 2009; Sollid, 2002). The 
presence of autoantibodies to TG2 in all celiac patients (Dieterich et al., 1997; Leffler and 
Schuppan, 2010; Pallav et al., 2012) confirms a central role of TG2 in the etiology of the 
disease. The structural requirements of gluten and TG2 modification have been well 
established (Vader et al., 2002). The spacing between glutamine and proline residues, the 
two most abundant amino acids in gluten, has a major effect on the efficiency of 
deamidation by TG2. In the sequences QP and QXXP, the Q is not a target for TG2, 
while in the sequences QXP, QXXF(Y, W, M. L, I or V) the Q is a very good target for 
deamidation. Interestingly, besides the anticipated deamidation of QXP in pep 2 and 
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pep3, deamidation of a second glutamine in both peptides was noted. In pep2, the 
remaining Q residues occurred either in the QL or QP context, or at the C-terminus. In 
pep3, the second deamidated Q residue was inevitably in the QP context. The results 
suggest that TG2-mediated deamidation may proceed at unpreferred sites, or that some 
(minor) unspecific deamidation had occurred during incubation in PBS, in a TG2-
independent fashion. Indeed, the non-TG2 incubated pep2 and pep3 already showed 
some level of deamidation. 
As shown in Figure 12, cleavage occurred after Q in the three “QLPY” repeats, 
which is a preferred deamidation site for TG2 and also present in multiple T cell epitopes 
(Sollid et al., 2012). And in the 26-mer, four of the potential TG2 recognition sites, 
“QQP”, were cleaved after the first Q. Thus, R. mucilaginosa hydrolysis specificities 
eliminate some predicted TG2 recognition sites of the major immunogenic domains. This 
is consistent with our results showing that the fragments in the degradation mixtures are 
not cross-linked as efficiently as the untreated proteins in TG2 mediated crosslinking and 
deamidation assays.  
At present, the only effective treatment for CD is strict life-long gluten free diet 
(Fasano, 2012). R5 monoclonal antibody-based analysis has been recommended by the 
Codex Alimentarius and the Food and Drug Administration for the detection of gluten 
contaminants in gluten-free foods to ensure the safety for celiac patients (Lester, 2008; 
Mendez et al., 2005; Valdes et al., 2003). As indicated the preferred binding epitope for 
the R5 antibody is the potentially celiac toxic epitope QQPFP. Besides this epitope, the 
 72 
 
R5 antibody also binds to structurally similar pentapeptide repeats, such as LQPFP, 
QLPYP, QLPTF, QQSFP, QQTFP, PQPFP, QQPYP, QQQFP, QLPFP, and QVQWP 
(Kahlenberg et al., 2006; Osman et al., 2001; Valdes et al., 2003). Among these epitopes, 
the 33-mer contains LQPFP (one repeat, strong binding) and QLPYP (three repeats, 
weaker binding). The 26-mer contains two copies of the strong binding epitopes QQPFP, 
and one weaker binding epitope QQPYP. The different predicted affinities of the 33-mer 
and 26-mer for the R5 antibody may explain the higher competition (lower OD values) of 
the 26-mer in the competitive ELISA at the starting point. Given the recognition of a 
broad range of epitopes by R5, abolishment of all epitopes by R. mucilaginosa enzymes 
would be unlikely. Nevertheless, we observed a clear reduction in binding over time to 
Rothia-incubated gliadins, and 26-mer peptide, consistent with the cleavage of R5 
binding epitopes by R. mucilaginosa as decoded by MS (Figure12). Although the 
elimination of epitopes in the 33-mer was less effective than in the 26-mer, MS results 
indicated that R. mucilaginosa showed hydrolytic activity toward all the three major 
immunogenic epitopes comprised in the 33-mer. R5 antibody based analysis has been 
used to detect gluten in food, and it binds to all peptides in the N-terminal part of α-type 
gliadin known to induce responses in patients with coeliac disease after in vivo gluten 
challenge (Kahlenberg et al., 2006), although there is no study to show a direct 
correlation of R5 antibody and immunogenicity in patients (Lester, 2008). Therefore, the 
R5 results have to be interpreted with some caution. However, the binding domains of R5 
are present in multiple T-cell immune-stimulatory epitopes (Sollid et al., 2012), such as 
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PQPELPYPQ (DQ2.5-glia-α2), FRPEQPYPQ (DQ2.5-glia-α3), PQQSFPEQQ (DQ2.5-
glia-γ1), QQPEQPYPQ (DQ2.5-glia-γ3) , PQPEQPFPW (DQ2.5-glia-ω2), PQPEQPFPQ 
(DQ2.5-hor-2), EQPQQPFPQ (DQ8-glia-γ1a), EQPQQPYPE (DQ8-glia- γ1b), 
PQQSFPEQE (DQ8.5-glia-γ1), and they are associated with HLA types most commonly 
carried in patients with CD (DQ2.5, DQ8 and DQ8.5). Taken together, the cleavage 
activities directed at immunogenic epitopes, the impaired TG2 recognition, and reduced 
R5 binding are strong indicators that R. mucilaginosa hydrolysis diminishes the toxicity 
of gliadins and derived peptides. CD-patient derived T-cell responses to Rothia-incubated 
gliadins as well as in vivo challenge with Rothia-pre-digested gliadins should lend further 
support to the potential beneficial effects of the Rothia enzymes in the treatment of CD.    
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CHAPTER III 
Comparative Analysis of the Endogenous Gluten-Degrading Enzyme Activities and 
Oral Microbiomes in Health and CD 
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3.1 Introduction 
Up to now, the etiology for CD is not completely understood. Carrier status of HLA-DQ2 
and/or HLA-DQ8 is a major risk factor in that all CD patients contain either of the two 
alleles. Carrier status however does not automatically mean disease development, since 
over 25% of the population carries HLA-DQ2 or HLA-DQ8, and only ~1% of the 
population develop CD (Kakleas et al., 2010; Monsuur et al., 2008; Wessels et al., 2014). 
Other factors such as bacterial or viral infections, early feeding practices, genes outside 
of HLA-DQ (e.g. IL-2, IL-21 genes) and differences in GI microbiomes have also been 
reported to be potentially implicated in the disease development (Challacombe et al., 
1997; Howdle et al., 1991; Kagnoff et al., 1987; Mahon et al., 1991; Norris et al., 2005; 
Pozo-Rubio et al., 2012; van Heel et al., 2007).  
Gut microbial compositions differ in health and CD (Sanz et al., 2011). For 
instance, increased numbers of enterobacteria and staphylococci are found in patients 
with CD, and levels are restored to those in healthy subjects after adhering to a gluten 
free diet (Collado et al., 2008; Nadal et al., 2007; Sanz et al., 2011). An increased number 
of potentially harmful Bacteriodes and virulent E. coli, and decreased levels of harmless 
Lactobacillus and Bifidobacterium in CD patients persist regardless of the diet. It has  
therefore been suggested that the levels of these species may be more diagnostic for the 
sensitivity to develop CD (De Palma et al., 2010; Nadal et al., 2007; Sanchez et al., 2008; 
Sanchez et al., 2010; Sanz et al., 2011).   
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The oral cavity, the most upper part of the GI tract, is the entrance to the human 
digestive system. The human oral cavity is a complex environment colonized with a 
diverse collection of aerobic and anaerobic bacteria. The estimated amount of bacteria in 
dental plaque and saliva is 1011 bacteria/ gram of dental plaque, and 108 to 109 / ml of 
saliva (Li et al., 2005; Maukonen et al., 2008; Nisengard and Newman, 1994). Oral 
bacteria also exist in or attached to other surfaces, including tooth enamel surfaces, the 
gingiva, the gingival sulcus, buccal mucosa, tonsils, hard and soft palates. Due to specific 
bacterial adhesins and complimentary receptors on oral surfaces, oral bacteria exhibit 
different preference for colonization sites (Gibbons, 1989; Gibbons, 1976; Liljemar, 
1971; Whittaker et al., 1996). With a 16S rRNA gene-based sequencing technique, Aas 
and coworkers have identified totally 141 species representing six different bacterial 
phyla on nine oral surfaces of five clinically health subjects (Aas et al., 2005). Further 
studies on samples collected from various oral sources revealed that the oral cavity 
harbors at least 1179 different taxa, belonging to 14 bacterial phyla (Dewhirst et al., 
2010). Some species show association with oral diseases, e.g. S. mutans with caries and 
P. gingivalis with periodontal disease, but the majority of oral colonizers are commensals 
with potential beneficial functions for the host.  
We previously reported that bacteria contained in human dental plaque and saliva 
exhibit proteolytic enzyme activities towards gliadins domains (Helmerhorst et al., 2010; 
Zamakhchari et al., 2011). Twenty two oral gliadin-degrading strains were isolated, 
representing seven species: Rothia mucilaginosa, Rothia aeria, Actinomyces 
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odontolyticus, Streptococcus mitis, Streptococcus sp., Neisseria mucosa and 
Capnocytophaga sputigena (Fernandez-Feo et al., 2013). Enzymatic activity was tested 
towards five derivatized enzyme substrates containing tripeptides that are common in the 
immunogenic gliadin domains. Among these, the Z-YPQ-paranitroanilide substrate was 
most frequently and most rapidly cleaved, pointing to microbial glutamine endoprotease 
cavity. Cleavage of gliadin-derived 33-mer and 26-mer peptides, containing multiple 
immunogenic domains, was also demonstrated for the identified species.  
In the oral cavity, oral microbes are mixed with the food bolus during mastication, 
and swallowed to reach the stomach and other parts of the upper GI tract. Since the 
identified microbes exhibit gluten-degrading activity, it is reasonable to postulate that 
they might be involved in gluten digestion in vivo, already starting in the oral cavity 
before the food bolus reaches gastric juices (containing pepsin) and pancreatic juices 
(containing trypsin and chymotrypsin). This early phase of saliva associated digestion is 
of particular interest when oral microbes digest gluten domains that are otherwise 
resistant to the gastric and pancreatic digestive enzymes. The trypsin/chymotrypsin 
resistant gluten domains are also highly immunogenic in CD and natural oral digestion 
might thus abolish the epitopes. 
In this study, we hypothesized that the endogenous salivary gluten-degrading 
enzyme activities and the oral microbial flora of healthy and CD patients are different. 
The studies may demonstrate salivary activity differences toward gluten substrates in 
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health and CD or reveal disease-specific microbial signatures. Both would have the 
potential to help in the diagnosis of CD.  
  
 79 
 
3.2 Materials and Methods 
 
3.2.1 Subjects and inclusion/exclusion criteria 
WS was collected from four groups of subjects: 1. Healthy subjects (HC) having no signs 
(genetic, serological or histological) or symptoms of CD or gluten sensitivity and 
presenting in overall good health; 2. Non-celiac patients (GI) suffering from non-immune 
mediated gastrointestinal symptoms and in whom CD was excluded by serological and 
histological testing 3. Celiac disease patients (CD) with positive anti-deamidated gliadin 
peptide (dGP) and/or anti-tissue transglutaminase (TG2) antibodies (Leffler and 
Schuppan, 2010), and duodenal villous atrophy at diagnosis and who were adhering to 
and being responsive to a gluten-free diet (GFD); and 4. Refractory celiac disease 
patients (RCD) which were previously diagnosed as CD and met criteria for RCD after a 
minimum of six months on the GFD (Abdallah et al., 2007). All subjects were recruited 
in Boston; CD, RCD and non-celiac GI subjects were recruited in Beth Israel Deaconess 
Medical Center and HC subjects were recruited at Boston University Goldman School of 
Dental Medicine. All subjects enrolled were of age 18 years and older and able to comply 
with study requirements and to provide informed consent, in person or via a legal 
guardian. Exclusion criteria were illicit drug or excessive alcohol use, having unstable or 
uncontrolled heart disease, kidney disease, and liver disease, suffering from a clinically 
defined and diagnosed mental illness, suffering from dry mouth complaints or displaying 
overt signs of dental or periodontal health issues.  
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3.2.2 Whole saliva (WS) collection 
Donors refrained for at least one hour from eating, smoking, drinking (except water), 
mouth wash (except water) and tooth brushing. Donors were asked to rinse their mouth 
with water three times and were then given a 20cm x 20cm parafilm for masticatory 
stimulation of saliva flow. Whole saliva (WS) was collected into graduated 50 ml 
centrifuge tubes placed on ice. The time for the collection of 10 ml WS was recorded. 
After vortexing, the collected WS was separated into 1 ml aliquots and five were 
centrifuged at 16,000xg for 10 min at 4°C to separate the WS supernatant (WSS) from 
the WS pellet (WSP). All WS, WSS and WSP were immediately frozen at -80°C and 
stored until analysis. 
 
3.2.3 Enzyme activity analysis of WS for Z-YPQ-pNA 
To study salivary microbial enzyme specificities directed at gliadins, we used chemically 
synthesized Z-YPQ-pNA (21st Century Biochemicals, Marlboro, MA), with Z 
representing benzyloxycarbonyl (protective group) and pNA representing para-
nitroanilide (reporter group). Z-YPQ-pNA was dissolved in 75% dimethyl sulfoxide to 10 
mM. From this solution, 4 µl was mixed with 200 µl WS (final substrate concentration 
200 µM). Substrate hydrolysis was monitored spectrophotometrically at 405 nm. The 
experiment was done in triplicate for each subject sample. The average maximum rate of 
hydrolysis in each patient’s WS was calculated from the three independent graphs, and 
compared. 
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3.2.4 Assessment of degradation of the 33-mer in WS 
The gliadin-derived immunogenic epitope 33-mer 
(LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF) was synthesized at a purity of 95% 
(21st Century Biochemicals, Marlboro, MA). The 33-mer peptide was added at a final 
concentration of 250 µg/ml to WS. After vortexing briefly, the mixture was placed in a 
37°C water bath. After 2, 5, and 8h incubation, 100 µl aliquots were removed, boiled for 
10 min to deactivate enzyme activity.  
 
3.2.5 RP-HPLC 
Surviving 33-mer peptide in the collected samples WS samples was monitored by 
Reversed-Phase High Performance Liquid Chromatography (RP-HPLC). Control 
experiments were performed in boiled WS samples (n=3).  The RP-HPLC methodology 
used was described in Chapter 2 Material and Methods (2.2.4). Briefly, the 100 µl sample 
aliquots were mixed with 900 µl 0.1% TFA, and subjected to C18 RP-HPLC. 
 
3.2.6 Whole saliva pellet (WSP) DNA isolation 
WSP from 1ml WS was used to isolate bacterial DNA using the MasterPure Gram 
Positive DNA Purification Kit (Epicentre, Madison, USA) according to manufacturer’s 
instructions. Briefly, to each aliquot of WSP 150 µl TE buffer containing Ready-Lyse 
Lysozyme was added and samples were incubated for 16h at 37°C. Subsequently, 150 μl 
of Proteinase K/Gram Positive Lysis Solution was added followed by incubation at 65-
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70°C for 15 minutes. After cooling to room temperature, 175 μl of protein precipitation 
reagent was added to the 300 μl of lysed sample. The supernatant was separated from the 
debris by centrifugation at 16,100g at 4°C for 10 minutes, and transferred to a clean 
microcentrifuge tube. An aliquot of 1 μl of RNase A (5 μg/μl) was added and incubated 
at 37°C for 30 min. After incubation, 500 μl of isopropanol was added, and the DNA was 
pelleted by centrifugation at 4°C for 10 min at 16,000g. The supernatant was removed 
and the pellet was washed once with 70% ethanol, and suspended in 50 μl of 10 mM Tris 
(pH8.0). The DNA was kept at -20°C until analysis. 
 
3.2.7 16S rRNA gene amplicon library sequencing and analysis  
Microbial diversity analysis in the WSP samples was studied by sequencing of the 
amplified V3–V4 hyper-variable region of the 16S rRNA gene as described by Caporaso 
et al. (Caporaso et al., 2011) with some modifications. In brief, WSP DNA (50 ng) was 
amplified with 341F/806R universal primers (V3-V4 region) and 5 PrimeHotMaster Mix 
(5 Prime). The PCR samples were purified using AMPure beads (Beckman Coulter, 
Milan, Italy) and then quantitated with the Nanodrop (ThermoScientific, Tewksbury, 
MA). Equal amount of libraries were pooled into 1 tube (100ng/library). The pooled 
libraries were run onto a 2% agarose gel.  Bands were cut out at ~590 bps and DNA was 
extracted with Qiagen Minelute Gel extraction kit. The library was run on a bioanalyser 
(Agilent, Santa Clara, CA, USA) for quantitation. The quantified library was diluted to 
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12 picomolar following the Illumina protocol, spiked with 20% Phix, and analyzed on the 
MiSeq (Illumina) for sequencing according to the manufacturer’s instructions.  
Raw sequences were generated by paired-end sequencing (2x250).  Initial read 
quality was assessed by FASTQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) which will report per base 
quality and average sequence quality for the run. The length of the generated reads were 
250 bases for both forward and reverse sequences which allows us to merge together the 
overlapping portion of the paired reads.  This created a high quality longer read that will 
provide coverage of the entire V3-V4 target region.  Merging the paired end reads are 
accomplished through FLASH sequence software developed by the Salzberg lab (Magoc 
and Salzberg, 2011). This step not only merges the short reads but also acts as a filter of 
low quality sequences by removing any that cannot be successfully merged together.  In 
order to develop community diversity profiles the QIIME analysis pipeline was 
implemented (Caporaso et al., 2010).  The initial step in the QIIME pipeline of splitting 
libraries preps the sequences for downstream analysis and provides a second quality filter 
by removing any reads with an average quality score of < 20.  Reads were clustered into 
OTUs (Operational Taxonomic Units) through the open reference clustering pipeline.  A 
reference database such as HOMD or Greengenes (DeSantis et al., 2006; Dewhirst et al., 
2010) along with a 97% identity threshold was used to guide the clustering of reads.  Any 
reads that failed to cluster using the reference as a guide were sent into a de-novo 
clustering step where new OTUs were produced using the same 97% identity threshold.  
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Chimeric sequences can be a problem in downstream analysis and need to be removed 
before going forward.  To check for chimeras in the OTUs we used UCHIME (Edgar et 
al., 2011) in combination with the gold reference database 
(http://drive5.com/uchime/uchime_download.html). The QIIME pipeline assigned 
taxonomy to OTUs using the uclust algorithm (Edgar, 2010) and reference databases 
such as HOMD and Greengenes.   
 
3.2.8 Statistical Analysis 
SPSS 15.0 software was used for statistical analysis. Differences in Z-YPQ-pNA and 33-
mer degradation rates between groups were analyzed with the Mann-Whitney test. For 
the microbiota analysis, outliers were identified from boxplots generated in SPSS. The 
Kruskal Wallis test was used for comparing the level of microbiomes among the four 
groups as well as between every two groups. Significance was set at p<0.05.  
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3.3 Results 
 
3.3.1 Demographic information and saliva samples characteristics  
WS was collected from the four groups of subjects, 20 healthy controls (HC), 12 non-
celiac GI patients (GI), 21celiac disease patients (CD) and 8 refractory celiac disease 
patients (RCD). The patient demographics and WS sample characteristics (stimulated 
flow rate and protein concentration) are summarized in Table 5. The race and gender 
distribution of the healthy donors was matched to the CD groups by selecting healthy 
donors in age and race categories that matched the CD group. The average age of the 
RCD group was higher than that of the HC and CD subjects, consistent with the fact that 
RCD is usually diagnosed in older people (Rubio-Tapia and Murray, 2010). The 
stimulated WS flow rates did not differ between groups, and ranges are indicated. The 
average WS protein concentration was slightly higher in the RCD group compared to the 
HC group (p=0.022), but no statistical differences were found between any other two 
groups.  
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3.3.2 Determination of the hydrolysis of Z-YPQ-pNA in WS 
Z-YPQ-pNA hydrolysis rates were determined in all WS samples (Figure 16). In boiled 
saliva samples (n=3) no hydrolysis was noted, confirming that the hydrolysis observed is 
enzyme-mediated (data not shown). Maximum substrate conversion rates were 
determined from the maximum slopes of three enzymatic reaction curves obtained for 
each WS sample. The initial absorbance within the first two hours, which gradually 
decreased overtime, was excluded for analysis, since it was caused by non-specific 
phenomena. Data are expressed AU/min. The average rates were similar between groups, 
2.36 ± 0.23, 2.03 ± 0.62, 2.98 ± 0.23, and 2.37 ± 0.29 AU/min (mean ± S.E.) in the HC, 
GI, CD and RCD groups, resp. Among the four groups, the CD patients showed a trend 
of having somewhat higher rates of cleavage of YPQ-pNA compared to the other groups. 
The difference was statistical significant between CD and GI groups (p=0.003) (Figure 
17A), but not between CD and HC (p=0.106) or CD and RCD (p=0.164). When the WS 
YPQ-cleavage activity was normalized to the total protein concentration (maximum YPQ 
cleavage rate / WSS protein concentration) a similar trend was observed with statistical 
difference found between GI and CD groups (p=0.06) (Figure 17B). To calculate the total 
“enzyme output”, the enzyme activity was multiplied by the WS flow rate (maximum 
YPQ cleavage rate x salivary flow rate), a measure for how much activity is actually 
being swallowed per time unit (Figure 17C). In this parameter, no statistically significant 
differences were found between the groups.   
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Figure 16. Rates of Z-YPQ-pNA substrate hydrolysis by enzymes in WS from HC, GI, 
CD, and RCD patients. Aliquots of 200 µl WS from each patient were incubated with 200 
µM Z-YPQ-pNA at 37°C. Hydrolysis was monitored spectrophotometrically at 405 nm. 
Plotted are the averages of three kinetic curves obtained for each individual. The 
variation in in the maximum rates within triplicates was on average 10.6%.   
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Figure 17. Hydrolysis rates of Z-YPQ-pNA substrate in WS.  A, The average maximum 
Z-YPQ-pNA hydrolysis rates of three independent curves of each individual in HC, GI, 
CD, and RCD groups. Statistical difference was found between GI and CD group 
(p=0.003, Man Whitney test). B, Plot of WS enzyme activity (maximum rate) divided by 
WSS protein concentration. Statistical difference was found between GI and CD group 
(p=0.006, Man Whitney test). C, Plot of the WS enzyme activity (maximum rate) 
multiplied by individual salivary flow rates. In the plots, the middle horizontal lines 
indicates the median, and the top and bottom lines indicate the first and third percentile, 
respectively. 
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3.3.3 Degradation of the 33-mer in WS  
Degradation of the 33-mer, a highly immunogenic gliadin-derived peptide, was studied in 
WS of all subjects. Degradation was monitored by RP-HPLC. The approach was feasible 
since the 33-mer eluted around 66 minutes whereas the WS salivary proteins eluted 
between 27 and 64 min (Figure 18). An example of the 33-mer degradation in WS from 
one subject in each group is shown in Figure 19. The peak height of the 33-mer peptide in 
the RP-HPLC chromatogram was measured at the 4 examined time points and plotted. 
The 33-mer peak degradation curves in WSS for all subjects are plotted (Figure 20). All 
samples were analyzed and from the peak height vs time plots, the initial rate of 
hydrolysis (between 0-2h) and the t½, representing the time needed to degrade 50% of 
the added 33-mer peptide, were calculated (Figure 21A, B, respectively). The initial 33-
mer degradation rates appeared somewhat was faster in the CD group compared to the 
other groups, and was statistically significant between CD and GI groups (Figure 21A). 
In accordance with the faster degradation rates in the CD group the t1/2 values were lower 
in the CD group compared to the HC, GI and RCD patient groups, although the results 
were again only significant between GI and CD groups (Figure 21B). These faster 
degradation of the 33-mer in the CD patients was consistent with the higher YPQ-pNA 
cleavage rate in the same group. An alternative interpretation is that the rates in the GI 
group are lower.  
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Figure 18. Analysis of 33-mer and WS proteins by HPLC.   A, 33-mer peptide (25 µg, 
red trace) added to WSS (100 µl) from eight individual subjects (black traces). B, 33-mer 
incubated in saliva from one individual for 0, 2h, 5h and 8h.  The peptide was degraded 
in a time dependent manner, as shown by the reduction of 33-mer peak height over time.  
 
 
 
A 
B 
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Figure 19. Degradation of the 33-mer peptide over time in WS. Shown are representative 
graphs from 1 subject per group (HC, GI, CD, and RCD). Arrows point to the levels of 
residual intact 33-mer peptide in the various incubation samples which were used to 
quantitate the degradation rate. 
 
 
 93 
 
 
Figure 20. Degradation of the 33-mer in WS from all subjects. Plotted are the 33-mer 
peak heights vs incubation time in WS. 
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Figure 21. Comparison of 33-mer degradation rates in the WS. A: the initial 33-mer 
degradation rate in the first two hour of incubation. Although the CD group showed a 
trend for faster degradation rates, statistically significant differences were only found 
between CD and GI groups (Mann-Whitney test, p=0.048). B: t½ values, representing the 
time needed to degrade 50% of the originally added 33-mer amount. The average value in 
the CD group was statistically lower than those for the GI (Mann-Whitney test, p=0.01), 
consistent with the faster initial degradation rate.  
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3.3.4 Salivary microbiota of the HC, GI, CD and RCD subjects 
To identify if there is a difference in the salivary microbiota among groups, the microbial 
composition in WS from the HC, GI, CD and RCD subjects was analyzed by 16S rDNA 
MiSeq. The salivary microbiota was first compared at the phylum level among the groups 
(Figure 22). For all the subjects in four groups, the major microbes detected belong to 
Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria, and Proteobacteria. Among 
those, Bacteroidetes and Firmicutes comprising ~50% of the total microbes. The groups 
did not show statistical significances at the phyla level, except for Bacteroidetes which 
were higher in CD compared to HC and RCD groups (CD vs HC p=0.009; CD vs RCD 
p=0.029), and Fusobacteria, which were higher in GI and CD groups compared to the 
HC and RCD groups (CD vs HC p=0.006; CD vs RCD p=0.022; GI vs HC p=0.037) 
(Figure 23). We were most interested in examining potential differences in levels of 
bacteria that we previously identified as gluten-degrading species (Rothia mucilaginosa, 
Rothia aeria, Actinomyces odontolyticus, Streptococcus mitis, Streptococcus sp., 
Neisseria mucosa and Capnocytophaga sputigena.). We first compared those bacteria at 
genus level (Actinomyces, Rothia, Streptococcus, Neisseria, and Capnocytophaga) 
(Figure 24). These genera  together account for 36% to 62% of the total genera among 
the four groups. The Actinomyces was more abundant in the CD group compared to the 
HC group (p=0.033). No differences were found for other genera among the patient 
groups (Figure 25). At the species level, only a selection of the seven gluten-degrading 
species could be identified. These were Actinomyces odontolyticus, Streptococcus mitis, 
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and Neisseria mucosa. When comparing their levels between groups, no statistically 
significant differences were found (Figure 26). Lastly cluster analysis was performed, 
taking into account the overall microbial patterns. The patterns did not show evidence for 
a group-specific clustering (data not shown). 
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Figure 22. Composition and relative abundance (percentage) of bacteria detected at 
phylum level in WS of HC, GI, CD and RCD subjects. 
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Figure 23. Abundance of Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria, and 
Proteobacteria in four groups. Statistically significant difference was found for the 
phylum Bacteroidetes and Fusobacteria. The CD group showed more Bacteroidetes than 
HC and RCD groups (CD vs HC p=0.009; CD vs RCD p=0.029). GI and CD groups 
showed a higher abundance of Fusobacteria than HC and RCD groups (CD vs HC 
p=0.006; CD vs RCD p=0.022; GI vs HC p=0.037).  
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Figure 24. Percentage of WS bacteria in genus of Actinomyces, Rothia, Streptococcus, 
Neisseria, and Capnocytophaga. These five genus include the gluten-degrading species 
identified by our group.  
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Figure 25. Abundance of Actinomyces, Rothia, Streptococcus, Neisseria, and 
Capnocytophaga in the four groups. Actinomyces was more abundant in the CD group 
compared to the HC group (p=0.033). No statistical differences were found for other 
genera in the four groups.  
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Figure 26. Abundance of Actinomyces odontolyticus, Streptococcus mitis, and Neisseria 
mucosa in the four groups. No statistical differences were found for each species in the 
four groups.  
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3.4 Discussion 
The present study tested the hypothesis that healthy and celiac patients differ with respect 
to salivary enzyme activities targeting gluten, and in oral microbiomes, in particular in 
species that target gluten. The study started on the premise that oral enzymatic activities 
play a physiological role in the digestion of foods. Many oral microbes produce 
proteolytic enzymes (Jansen et al., 1995; Jie Bao et al., 2008; Katz et al., 2002; Tian and 
Ouyang, 2010), and the proteolytic degradation of certain proteins in WS can occur in a 
matter of minutes (Sun et al., 2009). Nevertheless, a solid role for oral microbial enzymes 
in the digestion of proteinaceous foods remains to be established. Well recognized is that 
the digestion of foods starts in the oral cavity (“prima digestio fit in ore”), and that 
digestive enzymes, such as amylase, are produced by the salivary gland. Amylase is 
produced by salivary glands, and by the pancreas. Its expression in both glands shows 
that digestion in saliva may be important, and cannot be underestimated. Thus our 
hypothesis was that gluten-degrading oral enzymes, produced by microorganisms, may 
participate in the natural in vivo digestion of gluten. Furthermore, we postulated that this 
degradation is physiologically relevant and different in health and CD.  
Our data showed that Z-YPQ-pNA hydrolysis rates and 33-mer degradation rates 
in WS, regardless of the patient group, were low. This observation may not be 
unexpected: only a selection of microbes in the oral cavity degrade gluten, and the 
gluten-degrading capacity of mixed oral fluid (whole saliva) is dependent on the levels of 
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such microbes in the mixture of bacteria in saliva.  The oral gluten-degrading species do 
not rank among the most abundant (Fernandez-Feo et al., 2013). 
Recently, Francavilla and coworkers investigated the salivary microbiota and 
metabolome of CD children (on a GFD) and healthy children (13 subjects in each group). 
The authors amplified the 16S rDNA V1-V3 region and used the pyrosequencing 
technology. Their study indicated that CD children showed increased level of 
Bacteroidetes and decreased level of Actinobacteria. They furthermore reported an 
extensive list of microbial differences at the species level, and found that R. mucilaginosa 
was higher in the CD group compared to the healthy control (p=0.05).  In our study with 
adult cohorts, the variable V3-V4 region was amplified, and sequenced using the MiSeq 
technology. At the phyla level, the CD group showed increased levels of Bacteroidetes 
and Fusobacteria compared to HC and RCD, but the relatively higher abundance of these 
phyla was also observed in GI controls, suggesting that these phyla were not related to 
CD. At the genus level, a difference was found in the abundance of Actinomyces between 
CD and HC groups. The gluten-degrading species Actinomyces odontolyticus in this 
genus didn’t show statistical difference among the four groups, suggesting that other 
species may have led to the increased Actinomyces in the CD group. Overall, rather large 
inter-individual variations in oral microbial colonization levels were observed, consistent 
with other reports (Cockburn et al., 2012), likely contributing to the observation that most 
comparisons were not significant. Unfortunately, the Rothia species individually could 
not be distinguished with sufficient confidence. qPCR with selective primers should 
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reveal whether there are differences in carriage of these species among the four groups. 
Additionally, metagenomic studies, focusing on enzyme genes rather than individual 
species, could reveal differences in the four patient groups. 
We did compare in this study the salivary gluten-degrading enzyme activities. 
Interestingly, while the overall enzyme activities towards Z-YPQ-pNA and the 33-mer 
were low, they tended to be highest in the CD group. The obtained results are a bit 
counter-intuitive, since more efficient degradation of immunogenic domains would be 
expected in the healthy cohorts. An explanation is that modestly enhanced enzymatic 
activities can actually be harmful to the CD host. When activities are low, the enzymes 
would likely incompletely abolish epitopes 
(http://www.enzymestuff.com/conditionceliac.htm). In that case, they may actually 
release domains from larger gluten proteins that have immunogenic properties, those then 
could more easily penetrate the endothelium to reach the lamina propria of the small 
intestine and cause inflammation.  
Overall, from a diagnostic perspective, salivary gluten-degrading enzyme 
activities towards Z-YPQ-pNA and 33-mer peptide, and overall oral microbiomes 
compositions, show insufficient discrimination in health and CD to be further exploited 
diagnostically. Nevertheless, qPCR of individual Rothia species, and metagenomics of 
enzyme genes should be further explored for this purpose. Our studies show a potential 
association between low salivary enzyme activity increases and CD, even though this 
increase was not observed in the RCD group. If it is true that small increases in 
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proteolytic degradation of gluten worsen their toxicity, then therapeutic applications with 
oral enzyme supplements must overcome this to have a beneficial effect in CD.   
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CHAPTER IV 
Assessment of Potential Gluten-like Properties of Salivary Proline-rich Proteins 
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4.1 Introduction 
Celiac Disease (CD) is a T-cell mediated-inflammatory enteropathy which manifests 
itself in genetically predisposed individuals. In its etiology both genetic and 
environmental factors are implicated (Kagnoff, 2007; Murray, 1999; Pozo-Rubio et al., 
2012). The major genetic risk factors are carriage of HLA-DQ2 heterodimers, expressed 
in 90-95% of CD patients, or HLA-DQ8 heterodimers, expressed in the remainder of CD 
patients (Kagnoff, 2007; Meresse et al., 2009; Pozo-Rubio et al., 2012). The primary 
environmental cause of CD is gluten, a heterogeneous mixture of glutamine- and proline-
rich storage proteins from wheat, rye and barley.  
Dietary gluten is omnipresent in the Western diet. According to their solubility in 
alcoholic solutions, gluten is divided into soluble gliadins based on their mobility at low 
pH in gel electrophoresis (comprising α/β-, γ-, and ω gliadins) (Wieser, 1996), and 
insoluble glutenins, which are grouped into high molecular weight (HMW-GS) and low 
molecular weight (LMW-GS) glutenins based on differences in molecular mass and 
disulfide crosslinking (Ribeiro et al., 2013; Shewry et al., 1995). Gluten proteins are 
unique because they have a high content of proline (P) and glutamine (Q). In the most 
abundant α/β-gliadins, γ-gliadins and LMW-GS, Q comprises 35-38% of the total amino 
acids, while P ranges from 13-17%. The high P content makes dietary gluten partially 
resistant to mammalian digestive enzymes, resulting in relatively large peptides that reach 
the small intestine, some of which contain immunogenic gluten domains of at least 9 
amino acids length that are antigenically presented by HLA-DQ2 or -DQ8 (Koning, 
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2005; 2012). Without exception, the immunogenic domains contain glutamic acid (E) 
residues that derived from Q deamidation by the ubiquitous enzyme tissue 
transglutaminase (TG2) in the lamina propria. The E residue facilitates strong binding to 
HLA-DQ2 or -DQ8 in a proline-rich sequence context (Sollid, 2000; 2002; Sollid et al., 
2012).  
Interestingly the otherwise rare feature of a high P and Q content is not only 
observed in gluten proteins, but also in a group of proteins present in high concentration 
in human saliva: the proline-rich proteins (PRPs). PRPs are divided into acidic and basic 
PRPs with similar P and Q composition. As in gliadins, both P and Q constitute 
approximately 50% of the total amino acids of PRPs (Helmerhorst et al., 2010). Acidic 
PRPs are encoded two genes containing five different alleles: Db, PIF, and Pa at the 
PRH1 locus, and PRP1 and PRP2 at the PRH2 locus. They are proteins of 150 residues in 
length, with the exception of the Db protein with 171 amino acid residues (Hay et al., 
1994; Iavarone et al., 2014). Pa protein contains a cysteine residue, and in human saliva 
is dimeric. The basic PRPs are encoded by five genes: PRB1, PRB2, PRB3, PRB4 and 
SMR3B. At three of these loci, polymorphic isoforms have been found that vary in length 
due to different numbers of repeat domains in exon 3 (Azen et al., 1987; Hay et al., 
1988). Most PRPs furthermore undergo post-translational fragmentation and continued 
degradation by oral microbial proteases. Therefore, human saliva contains a rich mixture 
of acidic and basic PRP-derived proteins and peptides. Saliva is continually swallowed, 
thus reaching the downstream regions of the GI tract. 
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Based on the structural similarities between gliadins and salivary PRPs, their 
shared destination in the gastro-intestinal tract, and the fact that dietary gluten-exclusion 
is not always an effective means to resolve inflammation in CD, we hypothesized that 
salivary PRPs and gliadins may share functional characteristics that are relevant in CD. 
The present investigation focused on structural as well as potential functional 
resemblances.  
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4.2 Materials and Methods 
 
4.2.1 Subjects and inclusion/exclusion criteria 
Subjects inclusion and exclusion criteria are described in Chapter 3.2.1.  
 
4.2.2 Whole saliva (WS) collection 
Whole saliva was collected as described in Chapter 3.2.2. 
 
4.2.3 Collection of Parotid Secretion (PS) 
A Curby cup was placed over the orifice of the Stensen's duct (Curby, 1953). Sour 
candies were provided to donors for stimulation of PS secretion. 10 ml PS were collected 
on ice and the collection time was recorded. Immediately after collection, the PS was 
aliquoted in 1.5 ml fractions which were immediately stored at -80°C until analysis.  
 
4.2.4 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Aliquots of 35 µl PS were boiled for 5 min in diluted 4x 2-[Bis(2-hydroxyethyl)amino]-
2-(hydroxymethyl)-1,3-propanediol (Bis-Tris) sample buffer and applied to NuPAGE® 
Novex® 12% Bis-Tris Gels (Invitrogen, Carlsbad, CA). Electrophoresis was carried out 
at a constant voltage of 120V for about ~1.5 hrs at room temperature. The gels were 
stained with 0.1% Coomassie Brilliant Blue R-250 in 40% ethanol and 10% acetic acid 
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for 16 h, and destained in 10% acetic acid for 2-3 days as described (Beeley et al., 1991a; 
Beeley et al., 1991b; Beeley et al., 1996).  
 
4.2.5 Anionic gel electrophoresis 
Anionic gel electrophoresis was conducted as previously described (Davis, 1964; 
Oppenheim et al., 1971; Ornstein, 1964) using the mini-gel system (Bio-Rad, Hercules, 
CA, USA). The separating gel contained 7.5% acrylamide, 0.375 M Tris (pH 8.9), and 
0.07% ammonium persulfate. The stacking gel contained 6.7% acrylamide, 41.7 mM Tris 
(pH 6.7), 0.3% riboflavin and 26.7% sucrose. Aliquots of 50 µl PS were dried using a 
speedvac (Savant, ThermoFisher Scientific, Waltham, MA) and resolved in sample buffer 
containing 0.06 M Tris-HCl (pH 6.7), 19.2 % sucrose and 11.9 µM bromophenol blue). 
The running buffer contained 24.9 mM Tris and 191.8 mM glycine (pH 8.3). 
Electrophoresis was performed at 120V for approximately 2 h. The gels were stained 
with 0.5% Amido Black in 7% acetic acid for 16 h, and destained with 7% acetic acid.  
 
4.2.6 DNA isolation from whole saliva pellet 
Whole saliva pellet DNA isolation was described in Chapter 3.2.6. 
 
4.2.7 PRH1 gene amplification with PCR 
Primers for the PRH1 gene were designed for amplification of exon 3 (Zakhary et al., 
2007). The forward primer was 5’-GTGATGGGAACCAGGATGATGG-3’, and the 
 114 
 
reverse primer was 5’-AAACTGGAATCGTACCTGTCATT-3’. Polymerase chain-
reaction (PCR) was performed on DNA isolated from WSP. The PCR reaction (total 
volume 25 μl) contained 0.3 μl WS pellet DNA (containing 20.7 µg to 195.3µg DNA, 
subject variation), 12.5 µl TopTaq Master Mix containing 0.92 units of TopTaq DNA 
Polymerase (Qiagen, Hilden, Germany), 0.5 μl forward and reverse primer mix (both 
final concentrations are 200 nM) and 11.7 μl RNAse free water (Qiagen). The PCR was 
performed in BioRad T100 Thermal Cycler PCR system (Bio-Rad, Hercules, CA, USA) 
under the following conditions (38 cycles): DNA denaturation at 94°C for 30 sec; 
annealing at 62°C for 1 min, and extension at 72°C for 1 min. The amplification products 
were separated on a 2.5% agarose gel and visualized with SYBR Safe DNA gel stain 
(Invitrogen, Carlsbad, CA, USA). 
4.2.8 Western Blot analysis 
Polyclonal anti-gliadin antibodies conjugated to peroxidase were purchased from Sigma 
(St Louis, MO, USA). PS proteins (48 µg) were separated by 12% SDS-PAGE 
(Invitrogen) and transferred by blotting to polyvinylidene difluoride (PVDF) membranes 
(Thermo Fisher Scientific, Rockford, IL, USA) at a constant current of 400 mA for 2 hr 
at 4°C. After blocking the blots with 5% nonfat dry milk at 4°C for 16 h, the membranes 
were washed three times with TBS-T (25 mM Tris–HCl, 125 mM NaCl, 0.1% Tween 
20), and then probed with horseradish peroxidase (HRP)-conjugated anti-gliadin 
antibodies (1:1000 diluted, in 5% non-fat milk) for 1 hr at room temperature. After 
washing three times with TBS-T, the binding antibodies were detected using the 
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enhanced chemiluminescent substrate (ECL) (Thermo Fisher Scientific, Rockford, IL, 
USA) according to the manufacturer’s protocol. Signals were visualized on an X-ray film 
(Denville, NJ, USA) using a Konica Minolta SRX-101A film processor (Konica Minolta 
Medical & Graphic, Inc., Shinjuku-Ku, Tokyo, Japan). 
 
4.2.9 Enzymatic treatment of gliadins and PS proteins 
Mixed gliadins (Sigma, St Louis, MO, USA) were dissolved in 0.1 N HCl to 20 mg/ml. 
Aliquots of 1.5 ml PS were diluted with 3.458 ml water and 42 µl concentrated HCl (final 
concentration 0.1 N). Pepsin (Sigma, St Louis, MO, USA) was added at an 
enzyme/protein (w/w) ratio of 1:100 (w/w) (Marsh, 2000; van de Wal et al., 1998b) with 
respect to gliadin and PS protein and the mixture was incubated for 4 h at 37°C. After 
adjusting the pH to 7.8 with NaOH, trypsin was added at an enzyme/protein ratio of 
1:100 (w/w), and the mixture was incubated for 4 h at 37°C. The enzyme and protein 
mixtures were then boiled for 10 min to abolish enzymatic activities. Subsequently, the 
protein mixtures were incubated with guinea pig tissue transglutaminase 2 (TG2; Sigma, 
St. Louis, MO, USA) at an enzyme/protein ratio of 1:5 (Marsh, 2000; van de Wal et al., 
1998a) in PBS (pH 7.2) supplemented with 1 mM CaCl2 for 4 h at 37°C. Controls were 
carried where the same amount of enzymes (PT-TG2) were incubated without gliadin or 
PS proteins.  
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4.2.10 Peripheral blood mononuclear cells (PBMCs) isolation 
PBMCs were separated from other blood cells by density gradient centrifugation as 
described (Boyum, 1968; Coligan, 2003), with minor modifications. Briefly, 30 ml of 
whole human blood was collected into heparinized vacutainer tubes, and diluted 1:1 with 
PBS (pH 7.2). Aliquots of 6 ml of the diluted blood were gently overlaid on 3 ml of 
Histopaque (Sigma-Aldrich, St. Louis, MO, USA). After centrifugation (900 x g, 30 
min), the blood cells were separated into layers, with PBMCs accumulating at the 
interface between the Histopaque and plasma/platelet layer. PBMCs were removed from the 
interface with a pipet and washed twice in PBS. The numbers of cells isolated were 
determined using a haemocytometer. PBMCs were then adjusted to 2x106 cells/ml in 
CTL serum-free test medium (Cellular Technology Limited, Cleveland, OH) containing 2 
mM L-glutamine (Gibco BRL-Life Technologies, Grand Island, NY), 100 U/ml 
penicillin and 100 µg/ml streptomycin and immediately used in the cytokine induction 
assays. 
 
4.2.11 Cytokine induction in PBMCs 
Aliquots containing 700 µg TG2 treated PT-gliadins or TG2 treated PT-PS proteins were 
dried with a SpeedVac and dissolved in 1.75 ml CTL serum-free test medium (final 
protein concentration 400 µg/ml) containing 2 mM L-glutamine, 100 U/ml penicillin and 
100 µg/ml streptomycin. Aliquots of 100 µl PBMCs in CTL medium (2x105 cells) were 
mixed with 50 µl PT-TG2-treated gliadins (final concentration 100 µg/ml) or/and PS 
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protein (final concentration 25, 50, 100 µg/ml), after adding CTL medium to a final 
volume of 200 µl. Controls contained PT-TG2 only, at concentrations used to treat the 
respective gliadin/PS protein samples. The PBMC/protein mixtures were incubated in a 
37°C incubator with humidified air and 5% CO2 for 24 hrs. After incubation, the cells 
were centrifuged at 15,300xg and the culture supernatant was collected. Secreted TNF-α, 
IL-10, IFN-γ, and IL-21 were quantitated using a Luminex cytokine assay according to 
the kit protocol (EMD Millipore Corporation, Billerica, MA, USA). Briefly, 25 µl PBMC 
culture supernatant along with 25 µl assay buffer were added per well of a 96 well 
microtiter plate. In other wells, aliquots of 25 µl cytokine standards (7 concentrations) or 
assay buffer (background control) along with 25 µl CTL media were added. To each 
well, 25 µl beads coated with antibodies specifically recognizing TNF-α, IL-10, IFN- γ, 
and IL-21 were added, and the plate was incubated at 4°C for 16 h while shaking. The 
wells were then washed twice with washing buffer, and 25 µl detection antibodies were 
added to each well. The mixture was incubated for 1 h at room temperature, and 25 μl 
Streptavidin-Phycoerythrin solution was added. After washing and adding 150 µl 
washing buffer (sheath fluid), the level of cytokines in each well were quantified using 
the Luminex MAGPIX 4.2 equipment operated by xPONENT system software (EMD 
Millipore Corporation, Billerica, MA, USA).  
  
 118 
 
4.3 Results 
 
4.3.1 Demographic information and saliva sample characteristics  
PS was collected from the four groups of subjects, healthy controls (HC), non-celiac GI 
patients (GI), celiac disease patients (CD) and refractory celiac disease patients (RCD). 
The patient demographics and PS sample characteristics (stimulated flow rate and protein 
concentration) are summarized in Table 5. The race and gender distribution of the healthy 
donors were matched to the CD groups. The average age of the RCD group was higher 
than that of the HC and CD subjects, consistent with the occurrence of RCD in older 
people (Rubio-Tapia and Murray, 2010). The stimulated PS flow rates did not differ 
between groups, and the average PS protein concentration was slightly higher in the RCD 
group compared to the CD group (p=0.037) but no statistical differences were found 
between any other groups.  
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4.3.2 PRPs in saliva from HC, CD, RCD and GI patients assessed by SDS-PAGE 
SDS-PAGE and a modified Coomassie blue staining method (Beeley et al., 1991a; 
Beeley et al., 1991b; Beeley et al., 1996) were used to assess the general pattern of all 
(acidic and basic) PRPs in PS from the four patient and control groups. The utilized 
method of destaining takes advantage of the metachromasia of PRPs which, upon 
destaining, turn pink or violet, while other proteins remain blue-stained. The aim was to 
determine if a distinct pattern was associated with a particular patient group. A gel with 2 
representative subjects from each group is shown in Figure 27, and gels of all subjects are 
shown in Figure 28. The results confirmed the reported PRP metachromasia, and the 
assignment of the bands was based on previously reported migration positions in the gel 
(Beeley et al., 1991b). From Figure 28 it is evident that the PRP protein patterns show 
substantial inter-individual variations, consistent with the large number of polymorphic 
isoforms in the acidic as well as in the basic PRP protein families. Based on the SDS gel 
patterns alone we could not identify a particular PRP pattern to be associated with a 
particular patient or the control group.  
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Figure 27. SDS-PAGE (12% gel) of PS from two subjects of each group. Aliquots of 35 
µl PS were loaded for each subject. The gel was stained and destained with Coomassie 
Blue R-250 using a modified destaining method (Beeley et al., 1991a). The PRPs stain 
pink or violet while other proteins stain blue. The assignment of the bands were based on 
previously reported migration positions in the gel (Beeley et al., 1991b). 
  
 121 
 
 
Figure 28. PS protein patterns of all subjects. Aliquots of 35µl PS from each subject 
were analyzed by SDS-PAGE (12% gel), and stained and destained with a modified 
method with Coomassie Blue R-250 (Beeley et al., 1991a). The PRPs stained pink or 
violet.  
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4.3.3 Acidic PRP isoforms in the HC, GI, CD, RCD groups.  
To be able to further distinguish the acidic PRPs from the basic PRPs, samples were 
analyzed by anionic PAGE which is uniquely suited to visualize the acidic PRPs. The 
purpose was to explore if there are specific bands patterns to be associated with the 
patients groups.  Figure 29A shows the aPRP isoforms which were previously purified in 
our lab (Oppenheim et al., 2007). Except for PIF-s and PRP1, all acidic PRP isoforms 
could be separated based on electrophoretic mobility. The identity of the Pa dimer (Pa-
Pa) was confirmed with the dissociation of dimer into monomers upon incubation with 
DTT (Figure 29A, far right lane). Figure 29B shows PS samples analyzed by anionic 
PAGE, with two patients per group. The PRP isotypes are indicated, with Db-f, PRP3, 
PIF-f, and PRP4 representing proteolytic degradation fragments of the original gene 
products Db-s PRP1, PIF-s and PRP-2, respectively. Since the Db band was faint in some 
patients and no purified Db protein was available for comparison, PCR was conducted on 
the PRH1 gene to detect the Db allele, which could be distinguished from the alleles at 
this locus (Pa and PIF) based on size. Results with two patients from each group are 
shown in Figure 29C, clearly showing that patients CD5 and RCD5 contain the Db allele 
while the others do not. All patients’ samples were analyzed by anionic PAGE (Figure 
30). Based on the gels and PCR results combined, for 41 out of 58 subjects, the alleles 
encoded at the PRH1 and PRH2 locus could be deciphered. The allele frequencies in each 
group were calculated (Table 6). The obtained frequencies matched reported frequencies 
of aPRPs in healthy subjects (Azen and Maeda, 1988; Hay et al., 1994). Statistical 
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analysis revealed that the alleles at the PRH1 or PRH2 locus did not differ between 
healthy and diseased groups.   
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Figure 29. Analysis of acidic PRP isoforms in human parotid secretion. A. Ornstein 
Davis of PRP isoforms. Lanes 1-5: pure and semi-pure PRP isoforms (20 µg 
protein/lane); Lane 6 and 7: Pa dimer incubated without and with DTT, respectively. B. 
Ornstein Davis gel electrophoresis of PS (50 µl/lane) from 2 subjects per group. C, 2.5% 
agarose gel of PCR products obtained after amplification with primers specific for the 
PRH1 locus. Lane 1, bp standard; lane 2-9, PCR products representing three products: Db 
(416 bp) and PIF/Pa (each 353 bp, indistinguishable). Shown are the results of two 
subjects per group.  
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Figure 30. Ornstein Davis gel electrophoresis of PS samples from all subjects. Aliquots 
of 50 µl PS from each subject were analyzed, and stained with Amido Black. E-06: 
mixed PS protein control sample loaded in each gel (100 µg/lane). 
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*Pearson's chi-squared test (p<0.05 is considered statistically significant) 
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4.3.4 Anti-gliadin antibody recognition of PS proteins 
We further investigated the structural similarities between salivary proteins and gliadin 
using a commercially available polyclonal anti-gliadin antibody recognizing multiple 
epitopes in gliadins which have not been specified. Figure 31A shows the SDS PAGE of 
gliadin (glia), amylase (amy) and PS protein from one CD patient. The blots incubated 
with anti-gliadin antibodies are shown in Figure 31B. The low amount of gliadin (0.1 µg) 
was barely observed in SDS-PAGE, but in the Western blot showed a strong signal, 
testifying to the sensitivity of the antibodies (Figure 31B). On the other hand, the 
relatively high amount of PS protein loaded (48 µg) showed very weak recognition by the 
anti-gliadin antibodies, with a single band at ~50 kDa matching the molecular weight of 
the major salivary protein amylase (Figure 31A,B). PS from all subjects showed a 
similar, cross-reactivity with the antibodies in 50 kDA range and a weaker reaction in the 
37-50 and in the >75 kDa region (Figure 32). While minor differences were noticed in 
band intensities among subjects, overall, no group-specific differences were noted. The 
results indicated that PRPs and gliadins, from an antibody recognition perspective, are 
significantly different, and importantly, there was no recognition of the salivary PRPs in 
the CD and RCD groups. 
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Figure 31. Gliadin, amylase and PS proteins. A, SDS-PAGE, 12% gel, Coomassie Blue 
R-250 stained. B, Western blot, incubated with anti-gliadin antibodies. Loaded amounts 
of samples are indicated. The chosen amount of amylase is comparable to its 
physiological amount in the loaded amount of PS.  
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Figure 32. Cross-Reactivity of anti-Glia-Ab with Salivary Proteins in all subjects. Mixed 
gliadins (0.1 and 0.06 µg) or salivary proteins (48 µg per lane) were separated by 12% 
SDS-PAGE and immunoblotted with anti-gliadin antibody conjugated to HRP (1:1,000 
dilution). Subjects in HC, GI, CD and RCD groups showed similar patterns of a cross 
reacting protein band in the ~50 kDa and >75 kDa regions. Differences between 
experimental groups were not apparent.   
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4.3.5 Cytokine secretion by PBMCs under stimulation of PS 
While the above studies suggested that there are no gliadin-like elements in PRP 
sequences based on the absence of gliadin antibody recognition, we investigated if 
similarities among the two protein species existed at the functional, i.e. immune 
stimulatory level. For this purpose we studied the induction of inflammatory cytokines 
critical in causing duodenal inflammation in CD. In the gastrointestinal tract, dietary 
gluten proteins are hydrolyzed to some extent by digestive enzymes, and selected 
glutamines undergo deamidation by TG2. Deamidated domains then bind with high 
affinity to HLA-DQ2 and -DQ8 (Figure 33A). We hypothesized that salivary PRPs, after 
being exposed to pepsin/trypsin and TG2 might exert immune stimulatory effects on 
PBMCs similar to equally treated gliadins by virtue of their structural similarity to dietary 
gliadins (Figure 33B).  
 The potential cytokine-inducing effects of PS proteins (100 µg/ml) from HC, CD 
and RCD patients were analyzed using PBMCs isolated from two CD patients (Figure 34). 
Gliadins at 100 µg/ml served as the positive control. Gliadins induced secretion of TNF-α 
and IL-10 (Figure 34), but not IL-21 and IFN-γ (data not shown). PT-TG2 treated PS 
proteins from the CD, RCD and HC groups induced TNF-α and IL-10 responses that were 
similar to those of the PT-TG2 negative control. These results showed that PS proteins do 
not exhibit immune-stimulatory effects on PBMCs as analogous to mixed gliadins. 
 
  
 131 
 
Figure 33. Schematic presentation of proposed influence of salivary PRPs on immune 
responses in CD. A, in the pathogenesis of CD, dietary gliadins are hydrolyzed to smaller 
fragments by human digestive enzymes (eg. pepsin, trypsin), and then deamidated by 
transglutaminase 2 (TG2). Deamidated gliadin fragments have higher binding affinity to 
HLA-DQ2/8 on APCs, and could activate T cell responses. B, based on the structural 
similarity and shared destination of salivary PRPs and gliadins, we hypothesized that 
salivary PRPs would also be hydrolyzed by human digestive enzymes, deamidated, and 
bind to HLA-DQ2/8 followed by activating T cells (hypothesis ①). In addition, or 
alternatively, salivary PRPs may compete with gliadins for HLA-DQ2/8 binding, thus 
indirectly interfere with the immune response triggered by gliadins (hypothesis②). 
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Figure 34. Effect of PS proteins from various sources on TNF-α and IL-10 production by 
PBMCs from CD patients (CD17, CD20). PBMCs were isolated from fresh blood of two 
CD patients. Gliadins (Glia) or PS from CD, RCD and HC subjects were digested with 
pepsin and trypsin (PT) and deamidated with tissue transglutaminase 2 (TG2). The level 
of TNF-α (A, B) and IL-10 (C, D) produced by PBMCs were analyzed after 24 h 
incubation to the respective samples. PT-TG2 alone served as the negative control (-Ctrl). 
Glia: 100 µg/ml; PS: 100 µg/ml; PBMCs: 1x106 cells/ml.  
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4.3.6 Influence of PS on gliadin-induced PBMCs cytokine production 
Having demonstrated that PRPs do not trigger immunity in PBMCs of patients and 
controls, it remained to be shown if salivary PRPs could interfere with the gliadin-
induced immune responses through competition, thus antagonizing gluten-triggered 
inflammation (Figure 33B). To test this effect, 25, 50 or 100 µg/ml of PS proteins were 
added together with 100 µg/ml gliadins (both PT-TG2 treated) to the PBMC culture 
(Figure 35). Experiments were carried out with PBMCs from the three CD patients. 
Consistent with the results in Figure 34, gliadins alone induced TNF-α and IL-10 in all 
three CD patients, and PT-TG2 treated PS induced background cytokine levels, similar to 
levels induced by PT-TG2 alone (negative control). PT-TG2 treated PS proteins in 
combination with PT-TG2 treated gliadins tended to increase cytokine induction. 
However, similar trends were observed when PT-TG2 (negative control) was added to 
PT-TG2 treated gliadins in the absence of PS protein. Therefore, the noted effects could 
not be ascribed to PS proteins (Figure 35). Taken together, the data demonstrate that PS 
proteins could neither increase nor ameliorate gliadin effects on PBMC cytokine 
production. 
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Figure 35. Effects of PS proteins on gliadin-triggered TNF-α and IL-10 production by 
PBMCs from CD patients. PBMCs from three CD patients (CD9, CD13, CD8) were 
analyzed separately. Gliadins (Glia), with or without increasing amount of PS from each 
patient were incubated with PBMCs. The levels of TNF-α (A, B, C) and IL-10 (D, E, F) 
produced by PBMCs were analyzed after 24 h incubation. All gliadins and PS were 
digested with pepsin and trypsin (PT) and deamidated with tissue transglutaminase 2 
(TG2). PT-TG2 alone served as the negative control (-Ctrl). Glia: 100 µg/ml; PS: 25, 50 
or 100 µg/ml; PT-TG2 alone (-Ctrl) contained three levels of enzymes used to treat the 
PS samples (referred to as 25, 50, 100). PBMCs: 1x106 cells/ml. Values represent the 
mean±SD of three independent samples.   
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4.4 Discussion 
Here we describe that, despite the high structural similarity and prevalence in the 
gastrointestinal system, salivary PRPs do not act similarly to gliadins to stimulate 
PBMCs of CD patients to produce cytokines. While PBMCs are not an optimal source of 
gliadin-reactive T-cells, they have been used successfully in other studies to detect 
gliadin immunogenicity. For instance, gliadin-specific peripheral lymphocytes have been 
used in studies of children with CD (Hansson et al., 1997), and of CD patients on a 
gluten-free diet, where exposure to gluten induced gluten-specific CD4+ T cells with gut-
homing potential (Brottveit et al., 2011; Frisullo et al., 2009; Han et al., 2013; Raki et al., 
2007). Furthermore, PBMCs have been successfully utilized to monitor CD patients’ 
immune responses to gluten challenge (Anderson et al., 2000; Anderson et al., 2005; 
Anderson et al., 2006; Harris et al., 2008; 2010; Lammers et al., 2011; Silano et al., 
2007).  In the present study, we stimulated PBMCs of CD patients to measure the 
secretion levels of TNF-α, IFN-, IL-21 and IL-10, cytokines that have been reported to 
be upregulated in CD (Forsberg et al., 2002; Meresse et al., 2008; Nilsen et al., 1998; 
Przemioslo et al., 1994). TNF-α, IFN- and IL-21 are major pro-inflammatory Th1 T cell 
cytokines in CD (Nilsen et al., 1998; Przemioslo et al., 1994; Fina et al., 2008). 
Conversely, IL-10 is mainly a product of regulatory myeloid and T cells, suppresses T 
cell responses, and has also been reported to be upregulated upon gliadin stimulation 
(Forsberg et al., 2002; Forsberg et al., 2007; Leon et al., 2005). Consistent with prior 
studies, gliadin stimulation of our PBMC enhanced the production of both TNF-α and IL-
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10; however, unexpectedly IFN- and IL-21 were not induced. One reason for the variant 
immune modulation by PT-gliadin may be due to different amounts of innate immune 
modulators in gliadin preparations, such as amylase/trypsin inhibitors (ATIs) that are 
highly protease resistant and stimulate innate immune responses via toll like receptor 4 
(Junker et al., 2012). PS protein though did not induce any of these cytokines, neither 
from CD nor from RCD saliva samples, indicating that PRPs from RCD patients are not 
different in terms of potential “gluten-like properties” from PRPs of CD subjects or 
healthy controls. Given that the cytokine responses to mixed gliadin may have been 
caused by the ATI constituent, the PBMC competition assay results should be interpreted 
with caution as to whether PRPs are not at all able to compete with gliadins. Planned 
experiments with duodenal biopsy/T cells and more highly purified or synthetic gliadins 
should provide more definitive answers.  
 Closer inspection of the structural constraints of gliadin epitopes and their 
interaction with the MHC class molecules HLA-DQ2 or -DQ8 suggests possible 
explanations for the non-stimulatory effects of PRPs. Deamidation of select Q residues 
by the enzyme TG2 is a critical step in CD pathogenesis and the spacing between Q and 
P residues in gliadins is an important determinant dictating TG2 recognition. In the 
sequences QP, QG, QXXP and QXXG, the Q is not a target for TG2, while in the 
sequences QXP, QXXF(X being Y, W, M. L, I or V), QXPF(X being Y, W, M. L, I or 
V), the Q can be deamidated (Vader et al., 2002). Gliadins and PRPs share foremost the 
high prevalence of P and Q residues in the XPQ context, and in both acidic and basic 
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PRPs, a large number of Q residues appear in the QGPP context. We incubated PRPs, 
like gliadins, with TG2 prior to exposure to PBMCs, to generate more potent epitopes. 
Projecting the known TG2-preferred gliadin sequences onto the PRPs, Q in QGPP may or 
may not be deamidated, since QXP is preferred by TG2，but QG and QXXP are not. The 
remainder of the Q residues in PRPs almost all fall into the non-preferred substrates for 
TG2. Noticeably, the N-termini of basic as well as acidic PRPs contain natural glutamic 
acid residues as well as aspartic acid residues, and thus negative charges in these proteins 
are naturally present.   
 A key question remains if the TG2-deamidated/naturally deamidated PRP peptides 
would bind to HLA-DQ2 or -DQ8. Based on the amino acid sequences of immunogenic 
epitopes and the structural resolution of some epitopes with HLA-DQ2 by X-ray 
crystallography, negatively charged residues (e.g. glutamic acid) are preferred at positions 
4, 6, and 7, and large hydrophobic amino acids at positions 1 and 9 (van de Wal et al., 
1996; Vartdal et al., 1996). Furthermore, many of the T-cell epitopes contain a P or a Q 
residue in positions 1 and 9, respectively (Sollid et al., 2012). HLA-DQ8 has a preference 
for negatively charged residues at anchor positions 1 and 9 (Godkin et al., 1997; Henderson 
et al., 2007; Tollefsen et al., 2006). In addition to epitope residues deeply buried into the 
DQ pocket, other residues facing outward, presumably towards T cells, are also important 
to elicit or modulate cytokine responses (Xia et al., 2006). Taken together, while salivary 
PRPs have structural similarity to gluten, and some domains would satisfy theoretic DQ2 
binding affinity, they may not satisfy all the requirements for forming immunogenic 
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domains for CD. These considerations are supported by the present results showing that 
PS protein didn’t induce cytokine production in CD patients’ PBMCs, and the fact that in 
most CD patients the symptoms characteristic for CD are alleviated once patients adhere 
to a gluten-free diet (when salivary proteins remain present).  
The delicate ability of the body to synthesize a group of proline and glutamine-rich 
proteins destined for the gastrointestinal tract that have such a high similarity to gluten but 
are nevertheless not participating in CD immune responses, may offer novel insights into 
the key structural elements of gliadins precipitating CD. For instance, which point 
mutations could transform a harmless PRP peptide into a TG2-substrate and immunogenic 
peptide binding to HLA-DQ2 or -DQ8. Thus structural features of harmless PRP peptides 
may help to generate non-toxic DQ2/8 blockers, and the primary structure of the naturally 
occurring salivary PRPs may serve as reference for such compounds or modifications of 
dietary gluten with the ultimate goal of reducing their immunogenicity and prevent 
duodenal inflammation in patients with CD. 
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CHAPTER V 
Conclusions and Perspectives 
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Rothia mucilaginosa, a natural microbial inhabitant of the oral cavity, cleaves gluten 
(gliadin) proteins at regions that are resistant to degradation by mammalian enzymes. We 
showed in this project that this cleavage greatly decreased the epitopes’ deamidation by 
TG2 and reduced their binding to R5 antibody. The importance of this finding is that it is 
a first indication linking gluten protein degradation by the Rothia enzymes to reduced 
immunogenicity. Gluten degradation does not automatically mean symptom 
improvement for CD patients. Dietary supplementation with the enzyme Peptizyde 
showed worsening of symptoms in CD patients 
(http://www.enzymestuff.com/conditionceliac.htm). The enzymes in this mixed 
preparation were not developed for or tested for immunogenic gluten epitope elimination. 
R. mucilaginosa-associated enzymes, in addition to other effective gluten-degrading 
enzymes already being evaluated clinically (ALV3; Alvine Pharmaceuticals Inc., San 
Carlos, CA, USA), and AN-PEP; DSM, Heerlen, the Netherlands), represent promising 
luminal enzyme therapeutics to neutralize the toxic effects of gluten/gliadin proteins in 
CD patients. The added value of the Rothia enzymes is that they possess unique cleavage 
specificities and are derived from a natural source, a colonizer of the human body, and 
expected to have less side effects than foreign substances when used therapeutically.  
To diagnose CD, positive serology and histological evidence for villi flattening in 
duodenal biopsies remain the gold standard. The search for additional diagnostic tests, 
especially those that could replace a biopsy test is ongoing. In this realm, we initiated 
studies to potentially discriminate between health and CD based on salivary gluten-
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degrading activities (Chapter III), salivary microbiomes (Chapter III), and salivary 
gluten-like proteins (Chapter IV). The studies were extensive, but unfortunately failed to 
uncover differences that could be explored diagnostically. Nevertheless, fine tuning of 
the assays to discover more subtle differences, at the microbiome or protein level, could 
reveal differences. For instance, specific probing for individual, highly active gluten-
degrading species such as Rothia species by qPCR could reveal differences among 
groups. Likewise, metagenomics approaches for overall gluten-degrading enzyme genes 
are promising to be further explored. Lastly, while overall PRP patterns did not yet 
provide evidence for differences among groups, it is feasible that CD and RCD patients 
carry point mutations in these proteins that would render them more gluten-like. In search 
for such PRP variants we are employing LC-ESI-MS/MS in collaboration with the groups 
of Dr. Castagnola in Rome. A single point mutation in an acidic PRP protein was found, 
unrelated to CD, and those results have been published (Iavarone et al., 2014). It shows 
the feasibility of discovering PRP variants with the techniques employed.  Overall, 
salivary microbes/PRPs may still show differences in health and CD but the methods so 
far used have not revealed them yet. In-depth sequencing and MS analysis would help 
elucidate the differences if they exist.  
Interestingly PRPs, despite their structural similarity to gluten immunogenic 
domains, did not elicit cytokine production in PBMCs. The limitations of PBMCs to 
study such inductions have been discussed in the previous Chapter, and future 
experiments should employ immunogenic T cells derived from duodenal biopsies to 
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further validate the absence of any immunogenic properties. At the same time, the 
observed lack of immunogenicity was not unexpected, since most CD subjects on a GFD 
heal from gluten-induced inflammation, thus indicating that salivary PRPs are tolerated. 
It suggests that despite high structural similarities, PRPs seems not to harbor gliadin-like 
elements which are relevant in CD. It is of high interest to further decipher the critical 
structural elements in gluten vs salivary PRP sequences that explain why gluten cause 
inflammation and PRPs do not. Our detailed structural analysis of PRPs and gluten 
summarized in Chapter I has already provided insights into which differences may be 
essential. Point mutations have been designed in basic PRP repeat domains that could 
lead to their recognition by TG2 and subsequent deamidation of glutamines. Furthermore, 
we have searched the PRP sequences for domains that would fit, perhaps with single 
amino acid substitutions, in the HLA-DQ2 binding pocket. The information to be gained 
would greatly help the design of novel gluten variants that lack immunogenicity and act 
as HLA-DQ2 blockers to eliminate the gluten-triggered immune responses and the 
ensuing inflammation in CD. 
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